f hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom e roche finance report f hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom finance report e roche finance report journey finance report recovery woman show cover roche finance report year appear cover report year midst receive treatment breast cancer photographed come powerfully cover year later enjoy life p e n n n v n p r n e r cancer modern care help advanced analytic enable roche expand colla b effective treatment create wealth new data insight oration combine available previously innovative opportunity strength unique tool therapy allow woman entire product lifecycle rd partner elevate personalise cover picture carry value chain ultimately improve healthcare new level life cover outcome patient patientsfinance brief key result sale core operate profit margin cer growth sale pharmaceutical diagnostic group change sale chf chf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant exchange rate average rate year end december definition cer core result core ep earning share exclude noncore item global restructuring plan amortisation impairment goodwill intangible asset allow assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give free cash flow assess group ability generate cash require conduct maintain operation indicate group ability generate cash finance dividend payment repay debt undertake merger acquisition activity free cash flow concept internal management business free cash flow concept fully describe page reconciliation ifrs cash flow free cash flow give therefinance brief roche roche group report strong overall result sale grow constant exchange rate cer ifrs net income increase cer core earning share increase cer major driver tax reform exclude core earning share grow sale group sale increase cer chf billion growth chf term pharmaceutical sale growth cer new medicine ocrevus perjeta tecentriq alecensa hemlibra oncology continue growth franchise avastin mabtherarituxan sale fall follow biosimilar launch europe biosimilar entry delay immunology sale increase lead actemraroactemra xolair diagnostic sale show growth cer immunodiagnostic business major contributor operating result core operating profit increase cer chf billion increase chf term research development expenditure grow cer chf billion core basis focus oncology neuroscience immunology therapeutic area research development cost represent group sale ifrs operating result include noncore expense pretax chf billion major factor chf billion impairment goodwill intangible asset notably chf billion relate intermune acquisition nonoperate result finance cost ifrs decrease chf billion base effect debt redemption loss income tax expense ifrs decreased cer chf billion effective core tax rate tax reform decrease rate percentage point net income ifrs net income increase cer chf billion increase chf term core earning share increase cer chf term cash flow operate free cash flow increase chf billion underlying cash generation division lead increase operate free cash flow cer chf term free cash flow increase cer chf term chf billion drive high operating free cash flow low income tax payment financial position net work capital decrease cer drive low inventory pharmaceutical division net debt decrease chf billion free cash flow cover dividend payment merger acquisition net debt percentage total asset credit rating strong moodys aa standard poor aa shareholder return dividend proposal increase dividend chf share represent nd consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr represent combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement general accounting principle noncurrent liability operate segment information current liability revenue provision contingent liability net financial expense debt income taxis equity attributable roche shareholder merger acquisition subsidiary associate global restructuring plan noncontrolle interest property plant equipment employee benefit goodwill pension postemployment benefit intangible asset equity compensation plan inventory earning share nonvoting equity security account receivable statement cash flow marketable security risk management cash cash equivalent relate party noncurrent asset list subsidiary associate current asset significant accounting policy account payable report roche management internal control financial report statutory auditor report general meeting roche holding ltd basel independent reasonable assurance report internal control financial report multiyear overview supplementary information roche security roche holding ltd basel financial statement note financial statement appropriation available earning statutory auditor report general meeting roche holding ltd basel financial review roche group financial review roche group result sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf roche group report sale growth constant exchange rate cer core operate profit growth ifrs net income increase core eps increase growth business impact tax reform sale growth drive new pharmaceutical medicine compensate grow impact biosimilar competition europe immunodiagnostic business diagnostic division group improve operating profitability productivity initiative support launch new product continue investment research development operate free cash flow chf billion increase high cash generate business partly offset high capital expenditure divisional operating result pharmaceutical diagnostic corporate group chf chf chf chf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operate free cash flow increase cer margin percentage point increase roche finance report roche group financial review sale pharmaceutical division chf billion billion new product major growth driver ocrevus perjeta tecentriq alecensa hemlibra contribute additional chf billion cer new sale ocrevus particular continued strong performance total sale reach chf billion continue growth launch major european market perjeta sale chf billion increase high demand earlystage adjuvant setting new product sale compensate initial impact biosimilar entry europe japan sales mabtherarituxan herceptin fall chf billion cer biosimilar version mabtherarituxan anticipate come market mid end biosimilar version mabtherarituxan herceptin avastin anticipate come market second half avastin sale higher mainly growth china sale growth immunology sale actemraroactemra xolair esbriet increase lucentis sale grow increase market share indication competitive pressure lead fall tarceva sale diagnostic division report sale chf billion increase cer major growth area centralise point care solution represent half division sale grow lead immunodiagnostic business molecular diagnostic sale increase growth cobas liat system blood screen virology business diabetes care sale increase ifrs operating profit increase pharmaceutical division diagnostic division result division impact impairment goodwill intangible asset current year comparative period result include chf billion impairment goodwill intangible asset large item chf billion relate intermune acquisition impairment goodwill intangible asset chf billion amortisation intangible asset chf billion chf billion expense global restructuring plan pharmaceutical division core operating profit increase cer sale increase cost sale increase volumedriven growth manufacturing cost increase royalty expense notably ocrevus marketing distribution grow product launch include ocrevus tecentriq research development cost grow especially oncology neuroscience immunology therapeutic area operate profitability benefit productivity initiative ifrs operating profit grow ahead core operating profit low restructuring charge low amortisation charge intangible asset operate free cash flow grow underlying business partly offset high capital expenditure notably chugai diagnostic division core operating profit increase cer increase sale cost sale grow increase sale volume partially offset favourable instrument reagent mix research development increase high spending highmidvolume system centralise point care solution development digital clinical decision support product ifrs operating profit grow core operating profit result low amortisation charge intangible asset operate free cash flow sale decrease high net work capital group operate free cash flow chf billion increase cer high cash generation business partly offset high capital expenditure free cash flow chf billion increase chf billion high operating free cash flow low income tax payment finance cost low ifrs basis chf billion base impact loss debt redemption prior year income tax expense low group effective core tax rate compare largely impact tax reform decrease effective core tax rate percentage point net income increase cer ifrs basis core basis drive case operating result impact tax reform exclude impact tax reform core ep increase result express swiss franc negatively impact appreciation swiss franc dollar brazilian real partly offset depreciation swiss franc euro net impact result express swiss franc compare constant exchange rate negligible sale percentage point impact core operating profit core ep roche finance report financial review roche group income statement change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest eps basic chf eps diluted chf core result sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core ep basic chf core eps diluted chf page definition core result core ep roche finance report roche group financial review merger acquisition group implement amendment ifrs business combination issue october amendment clarify definition business effect amendment particularly applicable acquisition carry roche group value acquire company consist right single product technology transaction account asset acquisition business combination result acquisition ignyta reassess account asset acquisition annual financial statement business combination disclose interim financial statement detail give note annual financial statement business combination april pharmaceutical division acquire control interest flatiron health inc flatiron health chf billion flatiron health market leader curation development realworld evidence cancer research oncologyspecific electronic health record software asset acquisition february pharmaceutical division acquire control interest ignyta inc ignyta chf billion acquisition group obtain right ignytas lead product candidate entrectinib orally bioavailable cnsactive tyrosine kinase inhibitor patient tumour harbour ros ntrk fusion pharmaceutical division complete acquisition tusk therapeutics ltd jecure therapeutics inc total cash consideration chf billion transaction june group enter merger agreement foundation medicine inc fmi acquire outstanding share fmis common stock own group price usd share cash fmi fully consolidate subsidiary group july transaction close fmi own subsidiary group cash consideration purchase public share include share issuable fmis outstanding stock incentive plan payment relate fee expense amount chf billion amount record equity change ownership interest subsidiary detail give note annual financial statement global restructuring plan group continue implementation resource flexibility plan pharmaceutical division address future challenge include biosimilar competition focus area plan include biologic manufacturing commercial operation product developmentstrategy group continue implementation major global restructuring plan initiate prior year notably strategic realignment pharmaceutical division manufacturing network programme address longterm strategy diagnostic division global restructuring plan cost incur millions chf diagnostic site consolidation plan total global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost include strategy plan diagnostic division include pharmaceutical division strategic realignment manufacture network resource flexibility biologic manufacturing network include plan outsource function share service centre external provider resource flexibility pharmaceutical division commercial operation global product developmentstrategy organisation roche finance report financial review roche group diagnostic division strategy plan diagnostic division incur cost chf million mainly employeerelate matter cost chf million include divestment subsidiary germany cost relate reorganisation molecular diagnostic business chf million spending plan division chf million site consolidation cost pharmaceutical division strategic realignment manufacturing network chf million mainly relate exit manufacturing site clarecastle ireland resource flexibility plan biologic manufacturing network incur cost chf million mainly relate asset impairment severance cost integration cost follow ignyta acquisition chf million global restructuring plan resource flexibility initiative pharmaceutical division incur cost chf million mainly employeerelate major item chf million plan outsource share service centre external provider plan include plan total chf million total global restructuring cost chf billion detail give note annual financial statement impairment goodwill intangible asset pharmaceutical division impairment charge chf billion major item net expense chf billion relate goodwill intangible asset intermune acquisition group comprehensive reassessment cashgenerating unit allocate goodwill pharmaceutical division detailed note annual financial statement reassessment light follow factor ongoing business transformation pharmaceutical division acquisition flatiron health effective april transaction fully acquire foundation medicine effective july early adoption amendment ifrs business combination issue october amendment clarify definition business transaction represent substance purchase business single asset group similar asset group review asset liability acquire intermune transaction detail include initial valuation report purpose acquisition account subsequent integration process conclusion review apart intangible asset represent acquire right esbriet relate defer taxation liability asset liability record group balance sheet revenue stream part acquire company synergistic benefit continue operation roche group substance december remain value group intermune acquisition estimate chf billion solely relate acquire right esbriet report group balance sheet product intangible asset use previously record impairment esbriet product intangible asset use partially reverse asset concern write estimate recoverable value chf billion income chf billion record main factor lead increase forecast cash flow relative previous year longterm forecast improvement sale expectation impairment chf billion record goodwill intermune acquisition surplus esbriet revenue support carry value goodwill synergistic benefit product therapeutic area accordingly separable recoverable value goodwill estimate zero fully impair reassessment cashgenerating unit allocate goodwill pharmaceutical division result impairment entry record align historic transaction transaction onwards use revise ifrs definition business detail section merger acquisition impairment pharmaceutical division total chf billion large impairment charge chf billion related trophos acquisition follow decision stop development compound acquire decrease contingent consideration provision mainly reversal remain provision relate trophos acquisition contribute income chf billion roche finance report roche group financial review diagnostic division diagnostic division record impairment charge chf billion major sequence business impairment charge chf billion impairment change commercialisation strategy relate product change timeline future product development decrease forecast cash flow revise sale assumption addition centralise point care solution business impairment chf billion record goodwill product intangible asset acquire constitution medical investor acquisition decision change commercialisation strategy diagnostic instrument haematology testing impairment charge chf billion pharmaceutical division large item charge chf billion partial impairment esbriet product intangible acquire intermune acquisition diagnostic division record impairment charge chf billion major sequence business detail give note annual financial statement legal environmental case significant development base development litigation notably accutane case provision previously hold release result income chf million detail give note annual financial statement net income earning share ifrs net income increase chf term cer dilute eps increase chf term cer core net income increase cer core ep increase core basis exclude noncore item global restructuring cost amortisation impairment goodwill intangible asset income impact accounting merger acquisition transaction alliance arrangement core ep increase cer exclude impact change tax rate effective january net income change change chf chf chf cer ifrs net income reconcile item net tax global restructuring plan intangible asset amortisation goodwill intangible asset impairment merger acquisition alliance transaction legal environmental case pension plan settlement transitional effect change tax rate normalisation equity compensation plan tax benefit core net income supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result roche finance report financial review roche group financial position financial position change change chf chf chf cer pharmaceutical net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt pension income taxis nonoperate asset net total net asset compare start year swiss franc appreciate currency notably euro less extent brazilian real partly offset depreciation swiss franc japanese yen dollar overall negative translation impact total net asset exchange rate give pharmaceutical division net working capital decrease cer mainly arise low inventory write off low inventory level certain mature product strong sale longterm net operating asset increase mainly result ignyta flatiron health acquisition offset goodwill impairment charge diagnostic division increase net work capital cer drive increase trade receivable business growth especially china japan increase inventory instrument pende installation longterm net operating asset diagnostic division decrease follow impairment charge goodwill intangible asset decrease net debt free cash flow chf billion partly offset dividend payment chf billion addition payment chf billion merger acquisition payment chf billion acquire ownership foundation medicine net pension liability low chf billion increase discount rate partially offset change fair value plan asset net tax liability increase mainly defer tax effect change net pension liability free cash flow free cash flow change change chf chf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay free cash flow page definition free cash flow detailed breakdown group operate free cash flow chf billion increase cer high cash generation business sale growth exceed increase cash expense partly offset high capital expenditure free cash flow chf billion increase cer compare arise high operating free cash flow low income tax payment roche finance report roche group financial review pharmaceutical division operating result pharmaceutical division operating result change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operating income revenue cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result page definition free cash flow roche finance report financial review roche group sale overview pharmaceutical division sale therapeutic area change sale sale chf chf cer oncology immunology neuroscience ophthalmology infectious disease therapeutic area total sale sale pharmaceutical division chf billion increase cer new product sale compensate grow impact biosimilar competition mabtherarituxan herceptin europe sale growth drive continue rollout new product ocrevus perjeta tecentriq alecensa hemlibra contribute additional chf billion cer new sale ocrevus particular continued strong performance total sale reach chf billion billion continue growth strong initial uptake market notably germany perjeta sale chf billion increase demand earlystage adjuvant setting continue growth neoadjuvant metastatic setting europe biosimilar competition negative impact continue erosion mabtherarituxan europe biosimilar launches herceptin europe mabtherarituxan herceptin japan sale product fall chf billion cer europe japan biosimilar version mabtherarituxan expect come market mid end biosimilar version mabtherarituxan herceptin avastin anticipate come market second half total mabtherarituxan herceptin avastin sale chf billion decrease oncology remain division large therapeutic area total growth new product perjeta tecentriq alecensa major contributor avastin sale increase mainly growth china herceptin sale high growth offset initial impact biosimilar competition europe mabtherarituxan sale fall follow biosimilar launches europe japan recent biosimilar launches limited impact mabtherarituxan herceptin sale main factor sale decline government price cut tecentriq increase alecensa increase report continue postlaunch uptake sale tarceva fall competitive pressure sale immunology grow actemraroactemra xolair esbriet increase lucentis sale grow drive increase market share indication infectious disease sale lower mainly patent expiry tamiflu major market new influenza medicine xofluza launch late initial sale chf million therapeutic area sale activasetnkase high launch rollout hemlibra medicine haemophilia continue sale chf million major eu market japan roche finance report roche group financial review product sale pharmaceutical division sale change sale sale chf chf cer oncology herceptin avastin mabtherarituxan perjeta kadcyla tecentriq alecensa tarceva xeloda gazyvagazyvaro total oncology immunology actemraroactemra xolair mabtherarituxan esbriet pulmozyme cellcept total immunology neuroscience ocrevus madopar total neuroscience ophthalmology lucentis total ophthalmology infectious disease tamiflu rocephin total infectious disease therapeutic area activasetnkase mircera neorecormonepogin total therapeutic area total sale total mabtherarituxan sale chf million chf million split oncology immunology therapeutic area roche finance report financial review roche group mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl rheumatoid arthritis ra certain type antineutrophil cytoplasmic antibody ancaassociate vasculitis mabtherarituxan regional sale change sale sale chf chf cer united states europe japan international total sale sale lower drive europe sale fall launch biosimilar eu market mabtherarituxan widely nearly approve indication sale increase growth immunology oncology segment drive subcutaneous formulation biosimilar launch expect mid end come market second half sale high international region particularly china broad market penetration japan sale adversely affect government price cut limit extent biosimilar version launch franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sale change sale sale chf chf cer united states europe japan international total sale perjeta regional sale change sale sale chf chf cer united states europe japan international total sale kadcyla regional sale change sale sale chf chf cer united states europe japan international total sale sale franchise grow chf billion sale herceptin sale high overall drive growth international region largely offset fall europe japan factor growth include rollout new formulation launch long duration treatment combination perjeta international region growth drive china broad market penetration herceptin sale europe lower biosimilar launch mid biosimilar launch impact herceptin sale japan sale perjeta grow increase demand region notably early breast cancer adjuvant set europe japan brazil kadcyla sale increase particular international region roche finance report roche group financial review avastin advance colorectal breast lung kidney cervical ovarian cancer relapse glioblastoma type brain tumour avastin regional sale change sale sale chf chf cer united states europe japan international total sale overall sale increase compare prior year international region sale grow particular broad market penetration china sale increase growth frontline ovarian cancer follow fda approval june colorectal cancer japan sale increase steady growth ovarian cancer europe sale decline france large factor actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis giant cell arteritis actemraroactemra regional sale change sale sale chf chf cer united states europe japan international total sale sale increase growth region drive continued uptake subcutaneous formulation notably recently approve giant cell arteritis indication japan major contributor sale increase major eu market brazil australia xolair moderate severe persistent allergic asthma aa chronic idiopathic urticaria ciu xolair regional sale change sale sale chf chf cer united states total sale sale grow drive demand growth chronic idiopathic urticaria expansion overall asthma market xolair remain market leader large allergic asthma indication ocrevus relapse form multiple sclerosis rm primary progressive multiple sclerosis ppm ocrevus regional sale change sale sale chf chf cer united states europe international total sale continuously grow demand indication growth drive new patient return patient ocrevus launch april comparative period include month sale initial launch phase ocrevus show strong initial uptake launch notably germany roche finance report financial review roche group lucentis wet agerelate macular degeneration wet amd macular oedema follow retinal vein occlusion rvo diabetic macular oedema dme diabetic retinopathy dr lucentis regional sale change sale sale chf chf cer united states total sale sale grew drive increase market share indication ongoing rollout prefille syrinx activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sale change sale sale chf chf cer united states international total sale sale higher lead mainly drive broad use hospital high number patient treat esbriet idiopathic pulmonary fibrosis ipf esbriet regional sale change sale sale chf chf cer united states europe international total sale sale grow growth europe drive launch new tablet formulation tecentriq advanced bladder cancer advanced lung cancer initial therapy nonsquamous nonsmall cell lung cancer nsclc sale grow chf million postlaunch uptake europe notably germany launch japan alecensa alkpositive nonsmall cell lung cancer global uptake continue increase sale chf million growth region notably report sale growth pharmaceutical division sale region change sale sale chf chf cer united states europe japan international eemea latin america asiapacific region total sale eastern europe middle east africa united states sale grew lead continued uptake ocrevus launch april franchise grow sale increase perjeta particular early breast cancer adjuvant setting sale growth herceptin lucentis sale increase ongoing rollout prefille syrinx increase market share approve indication hemlibra alecensa sale show strong initial uptake sale tarceva fall competitive pressure mandatory discount hospital b drug discount program increase high sale notably ocrevus oncology product roche finance report roche group financial review europe sale decline increase biosimilar penetration mabtherarituxan eu market notably germany france uk herceptin sale decline biosimilar launch major eu market mid negative impact sale partly offset launch ocrevus tecentriq perjeta alecensa gazyvagazyvaro particular germany actemraroactemra sale increase continue uptake subcutaneous formulation japan sale decrease government price cut annualise negative effect sale approximately particular mabtherarituxan herceptin sale negatively affect tamiflu sale decrease low government stockpile partially offset high sale tecentriq launch actemra roactemra alecensa international sale increase drive asiapacific latin america subregion sale china grow broad market penetration avastin mabtherarituxan herceptin sale brazil increase mainly high sale perjeta mabtherarituxan actemraroactemra turkey main driver growth avastin mabtherarituxan russia sale growth drive high sale franchise pharmaceutical division sale e lead emerge market change sale sale chf chf cer brazil china india mexico russia south korea turkey total sale competition generic medicine biosimilar group pharmaceutical product generally protect patent right intend provide group exclusive marketing right country patent right vary scope duration group required enter costly litigation enforce patent intellectual property right loss market exclusivity major product patent expiration challenge generic medicine biosimilar noncomparable biologic reason material adverse effect group business result operation financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically result significant reduction net sale relevant product manufacturer typically offer version low price patent expiry integral group business model future growth remain driven innovation late information clinical study include annual report page detail group product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm product sale affect recent patent expiry change chf chf cer comment tamiflu patent expiry major market intellectual property biologic involve multiple patent patent timeline individual product difficult exact date patent expiry biologic medicine group currently estimate basic primary patent major biologic medicine begin expire follow mabtherarituxan mid herceptin mid avastin mid eu subcutaneous formulation mabtherarituxan herceptin secondary patent right roche finance report financial review roche group composition matter patent mabtherarituxan herceptin eu expire biosimilar version mabthera rituxan launch europe mid market eu country major factor sale decline product europe biosimilar version herceptin launch major eu market mid japan biosimilar version mabtherarituxan herceptin launch sale adversely affect government price cut total sale mabtherarituxan herceptin fall chf billion cer europe japan group anticipate biosimilar version mabtherarituxan mid end come market second half product sale affect biosimilar launch change chf chf cer comment mabtherarituxan europe biosimilar launch mid herceptin europe biosimilar launch mid mabtherarituxan japan biosimilar launch early herceptin japan biosimilar launch mid base publicly available information competitor company group currently anticipate follow potential development uncertainty specific biosimilar version group biologic medicine approve food drug administration biosimilar version mabtherarituxan herceptin avastin come market second half sale mabtherarituxan herceptin avastin disclose previous section include regional breakdown summarise table note previous section yearonyear movement drive regular price volume change biosimilar competition factor overall picture total mabtherarituxan herceptin avastin sale change sale sale chf chf cer united states europe japan international total sale group derive royalty income patent know cabilly patent patent expire december certain residual income expiry group expect royalty income significantly low annual royalty income cabilly patent chf million operating result pharmaceutical division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product total ifrs core basis royalty operating income increase cer royalty income higher net increase sale royalty portfolio outlicense income increase high milestone income income chf million sale worldwide right konakion valcytecymevene exclude brazil japan chf million operating income mainly sale right establish product chugai roche finance report roche group financial review pharmaceutical division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer percentage sale cost sale increase percentage point manufacturing cost sale grow ahead sale growth volume growth high inventory writeoff partially offset favourable product mix royalty expense high increase sale certain product notably ocrevus noncore cost include amortisation impairment intangible asset mainly relate esbriet product intangible result include chf million impairment intangible asset consequently amortisation charge low end base improved future sale outlook previous impairment partly reverse chf million write pharmaceutical division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis core cost increase cer percentage sale decrease comparative period relative decrease result resource flexibility initiative transformation activity cost incur ensure increase patient access launch ocrevus tecentriq product restructuring cost relate resource flexibility initiative sale affiliate mainly amortisation intangible asset include flatiron health marketing intangible april pharmaceutical division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer percentage sale decrease percentage point oncology therapeutic area remain primary area research development tecentriq cancer immunotherapy portfolio key driver neuroscience immunology represent significant area spend addition pharmaceutical division inlicense pipeline compound technology total value chf million capitalise intangible asset impairment charge chf million include impairment chf million decision stop development compound acquire trophos acquisition impairment charge relate portfolio decision development compound different alliance partner roche finance report financial review roche group pharmaceutical division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill intangible asset merger acquisition alliance transaction legal environmental case pension settlement gain loss total ifrs basis core cost increase cer percentage sale remain stable administration cost increase mainly high legal service cost business taxis capital taxis fall decrease cost brand prescription drug fee restructuring cost relate site divestment impairment charge relate writeoff goodwill intermune trophos acquisition merger acquisition alliance transaction expense include cost relate flatiron health acquisition partially offset reversal remain contingent consideration provision trophos acquisition income chf million arise release legal provision notably accutane case roche pharmaceutical chugai subdivisional operating result pharmaceutical subdivisional operating result million chf roche pharmaceutical pharmaceutical chugai division sale external customer division core operate profit margin sale external customer operate profit margin sale external customer operate free cash flow margin sale external customer pharmaceutical division total core operating profit operating profit include elimination chf minus million unrealised intercompany gain roche pharmaceutical chugai chf minus million increase exchange rate japanese yen positive impact approximately chugai result express swiss franc group consolidated result cer report japanese yen sale chugai external customer low compare drive government price cut annualise negative effect sale approximately sale division increase increase sale actemraroactemra alecensa roche pharmaceutical chugais core operating profit increase income divestment establish product high gross profit sale roche pharmaceutical partially offset increase research development spending operate free cash flow chugai decrease capital expenditure new research facility construct yokohama roche finance report roche group financial review financial position pharmaceutical division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivables payable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start year swiss franc depreciate significantly dollar japanese yen result positive translation impact net operating asset partly offset appreciation swiss franc brazilian real euro exchange rate give net work capital net working capital decrease mainly low inventory high net liability receivables payable trade receivables high result high sale extend payment term ocrevus inventory decrease high inventory writeoff low inventory level certain mature product strong sale trade payable low follow settlement yearend position net liability receivablespayable increase high accrual rebate chargeback longterm net operating asset overall longterm net operating asset increase goodwill intangible asset increase acquisition ignyta flatiron health partly offset impairment intermune trophos asset major item capital expenditure chugais continue development new research facility yokohama japan roche investments site development basel kaiseraugst site switzerland south san francisco campus manufacture investment switzerland germany roche finance report financial review roche group free cash flow pharmaceutical division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale page definition free cash flow detailed breakdown pharmaceutical division operate free cash flow increase cer chf billion main contribution come underlie business operating profit net operating cash adjustment show increase net work capital low increase accrual rebate chargeback low inventory capital expenditure high land purchase yokohama japan chugais new research facility final payment genentech property lease option exercise investment intangible asset chf billion high roche finance report roche group financial review diagnostic division operating result diagnostic division operating result change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operating income revenue cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result page definition free cash flow sale diagnostic division report sale growth cer chf billion main contributor centralise point care solution lead immunodiagnostic business sale growth molecular diagnostic sale increase growth underlie molecular business main growth factor coba liat system blood screen virology business diabete care sale increase drive growth north america latin america offset low sale europe advance stain product portfolio main driver sale growth tissue diagnostic diagnostic division sale business area change sale sale chf chf cer centralise point care solution molecular diagnostic diabete care tissue diagnostic total sale roche finance report financial review roche group centralise point care solution business area major contributor overall divisional result sale growth primarily drive immunodiagnostic business account division sale clinical chemistry business factor sale development business grow especially asiapacific china europe middle east africa emea growth centralise point care solution regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale molecular diagnostic overall sale rise underlie molecular business report growth sale sequence business increase growth molecular business sale come cobas liat system blood screen virology business regional growth lead emea notably south africa order timing north america molecular diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale diabetes care sale increase drive north america latin america sale growth mainly come accuchek guide accuchek instant sale decrease emea region mainly result market dynamic france diabetes care regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale tissue diagnostic sale rise advanced stain portfolio contribute majority growth addition sale increase companion diagnostic primary stain business regionally growth lead north america emea asiapacific sale increase china main growth market tissue diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale roche finance report roche group financial review diagnostic division sale region change sale sale chf chf cer europe middle east africa emea asiapacific north america latin america japan total sale centralise point care solution molecular diagnostic main sale driver emea region division large market north america sale increase spread business area sale increase asiapacific mainly china grew drive centralised point care solution sales latin america rise mainly drive centralised point care solution diabetes care contribute centralised point care solution main factor sale increase japan diagnostic division sale e lead emerge market change sale sale chf chf cer brazil china india mexico russia south korea turkey total sale operating result diagnostic division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product royalty operating income core basis global restructuring plan total ifrs basis expiry late royaltybeare patent polymerase chain reaction pcr technology main factor low royalty income result outlicense income include settlement patent dispute year global restructuring income relate licensing deal portfolio prioritisation initiative diagnostic division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis roche finance report financial review roche group core cost increase cer sale growth increase high sale volume partially offset favourable instrument reagent mix core cost sale ratio decrease percentage point global restructuring cost mainly diagnostic strategy plan amortisation expense low product intangible asset corangeboehringermannheim acquisition fully amortise end impairment charge relate impairment intangible asset sequence business constitution medical investor acquisition diagnostic division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis increase core cost primarily high spending emerge market asiapacific emea region additionally increase result marketing software launch new digital solution core basis marketing distribution cost percentage sale decrease global restructuring cost consist organisational change diagnostic division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase high spending centralise point care solution portfolio highmidvolume system increase spending develop digital clinical decision support product ge healthcare collaboration spending sequence business high percentage sale research development core cost increase impairment charge relate intangible asset sequence business diagnostic division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill intangible asset merger acquisition alliance transaction legal environmental case pension settlement gain loss total ifrs basis core cost remain stable compare increase administration cost main driver high personnel cost integration expense recently acquire business viewic mysugr business taxis include income settlement agreement medical device excise tax percentage sale core cost decrease percentage point impairment charge goodwill sequence business legal expense mainly arise increase litigation cost sequence business roche finance report roche group financial review financial position diagnostic division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivables payable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start year swiss franc appreciate euro result negative translation impact net operating asset partly offset depreciation swiss franc dollar diagnostic division significant net asset position japanese yen depreciation swiss franc japanese yen minor impact exchange rate give net work capital net working capital increase cer trade receivables increase growth sale notably china japan inventory increase follow high demand emerge market drive high purchase instrument hold inventory prior installation trade payable increase result optimisation measure include extend payment term decrease net liability receivablespayable increase prepayment settlement significant yearend account payable accrual longterm net operating asset overall longterm net operating asset decrease cer mainly trigger decrease goodwill intangible asset result impairment charge increase provision restructuring litigation case capital expenditure relate instrument placement manufacturing site development china germany roche finance report financial review roche group free cash flow diagnostic division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale definition free cash flow detailed breakdown page operate free cash flow diagnostic division net cash inflow chf million decrease cer compare cash generation business measure operating profit net operating cash adjustment increase compare core operating profit growth difference high cash proceed disposal high noncash depreciation expense net work capital increase absorb chf million cash increase trade receivables inventory mention financial position comment capital expenditure chf billion mainly instrument placement notably china manufacturing site development china germany roche finance report roche group financial review corporate operating result corporate operating result summary change chf chf cer administration pension past service cost business taxis capital taxis general item general administration cost core basis global restructuring plan merger acquisition alliance transaction legal environmental case total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow page definition core result page definition free cash flow detailed breakdown general administration cost decrease cer core basis low project cost total cost ifrs basis increase restructure procurement corporate function change net operating asset mainly drive organisational change result transfer chf million asset mainly property plant equipment pharmaceutical division begin net work capital low increase note account payable abovementione transfer corporate operating free cash flow include restructure activity capital expenditure roche finance report financial review roche group foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer chf change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit exchange rate swiss franc december average december average usd eur jpy result express swiss franc negatively impact appreciation swiss franc dollar brazilian real partly offset depreciation swiss franc euro net impact result express swiss franc compare constant exchange rate negligible sale percentage point impact core operating profit core ep sensitivity group sale core operating profit change average foreign currency exchange rate swiss franc show table currency sensitivity impact increase average exchange rate sale core operating profit versus swiss franc chf chf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost mainly concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany chugais revenues cost denominate japanese yen roche finance report roche group financial review treasury taxation result treasury taxation result change change chf chf chf cer ifrs result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest financial position net debt pension income taxis financial noncurrent asset derivative net collateral net interest payable nonoperate asset net total net asset liability free cash flow treasury activity taxis pay total page definition core result page definition free cash flow financing cost core financing cost chf million decrease cer compare decrease mainly base effect loss debt redemption chf million interest expense include amortisation debt discount issue cost increase cer chf million increase interest rate net interest cost define benefit pension plan decrease cer chf million low discount rate end analysis financing cost give note annual financial statement detail debt repayment redemption give note roche finance report financial review roche group financial income expense core financial income expense net income chf million compare net income chf million net income equity investment chf million high gain equity investment net foreign exchange result reflect hedging cost loss unhedged position loss chf million compare net loss chf million analysis financial income expense give note annual financial statement income taxis group effective core tax rate decrease percentage point largely impact tax reform reduce effective core tax rate percentage point ifrs result decrease effective tax rate percentage point tax reform transitional impact result initial estimate effect defer tax balance tax rate change trueup adjustment transitional effect include noncore result ifrs result include impairment goodwill tax deductible net effect goodwill intangible asset line table detail group income tax expense relate balance sheet position give note annual financial statement analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate chf chf chf chf group effective tax rate core basis global restructuring plan goodwill intangible asset merger acquisition alliance transaction legal environmental case pension plan settlement transitional effect change tax rate normalisation equity compensation plan tax benefit group effective tax rate ifrs basis financial position decrease net debt free cash flow chf billion partly offset dividend payment chf billion payment merger acquisition chf billion buyout minority owner foundation medicine chf billion net pension liability decrease chf billion chf billion increase discount rate switzerland germany partially offset decrease fair value plan asset switzerland net tax liability increase mainly defer tax effect net pension liability december group hold financial longterm asset market value chf billion consist holding biotechnology pharmaceutical company acquire licensing transaction scientific collaboration free cash flow cash outflow treasury activity increase chf billion high pension contribution partly offset high proceed sale equity investment total taxis pay decrease chf billion low income tax payment follow tax reform partly offset time tax payment roche finance report roche group financial review cash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow millions chf pharmaceutical diagnostic corporate group operate profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay free cash flow operating profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay free cash flow definition free cash flow detailed breakdown page operate free cash flow increase cer chf billion major factor increase growth underlie cash generate operation chf billion cash revenue grow cash expense small decrease net working capital compare mainly low increase account payable capital expenditure chf billion drive site development basel south san francisco land purchase yokohama japan new research facility investment intangible asset chf billion increase chf billion compare come increase inlicensing activity pharmaceutical division net cash outflow treasury activity increase chf billion high pension contribution partly offset high proceed sale equity investment taxis pay low chf billion low tax payment follow tax reform partially offset time tax payment free cash flow chf billion high result higher operating free cash flow low income tax payment roche finance report financial review roche group net debt millions chf january cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow dividend payment transaction equity instrument merger acquisition net divestment subsidiary hedge collateral arrangement change ownership interest subsidiarie currency translation fair value movement change net debt december cash cash equivalent marketable security longterm debt shortterm debt net debt end period definition net debt net debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen pound sterling total dollardenominate debt include bond note denominate euro swap dollar consolidated result economic characteristic equivalent dollardenominate bond note net debt position group december chf billion decrease chf billion december decrease strong free cash flow chf billion partly offset annual dividend payment chf billion payment ignyta flatiron health acquisition chf billion payment chf billion take ownership foundation medicine issuance redemption repurchase bond note note annual financial statement impact liquid fund impact net debt position roche finance report roche group financial review contractual obligation commitment group obligation commitment set table carry value show consolidated balance sheet potential obligation show discount riskadjuste amount denominate foreign currency translate swiss franc december exchange rate contractual obligation commitment december millions chf potential obligation undiscounte carry year year year year total value onbalance sheet debt bond note debt contingent consideration provision account payable derivative financial instrument unfunde define benefit plan total onbalance sheet commitment offbalance sheet capital commitment property plant equipment operating lease contract manufacturing commitment alliance collaboration commitment total offbalance sheet commitment total contractual commitment reference note annual financial statement debt consist mainly bond note include principal interest group debt instrument debt mainly commercial paper carry value discount base interest rate inherent instrument contingent consideration provision potential payment arise merger acquisition carry value risk adjust discount unfunded define benefit plan mainly pension plan group german affiliate fully reserve pension obligation selffinance local affiliate operation carry value discount future company contribution group fund plan show table capital commitment property plant equipment noncancellable commitment purchase construction mainly roche site basel switzerland south san francisco operating lease future obligation noncancellable lease contract group implement ifrs lease point obligation report balance sheet contract manufacturing commitment future minimum takeorpay commitment purchase inventory arise group major longterm agreement external contract manufacturing organisation cmos alliance collaboration commitment potential upfront milestone payment group inlicense arrangement potential payment alliance partner asset deal year include assume project currently development successful potential payment year include asset deal provision legal environmental matter include table timing cash outflow uncertain contingent development matter question roche finance report financial review roche group pension postemployment benefit postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan chf million chf million plan classify define benefit plan group potential obligation minor relatively remote possibility arise plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource expense group define benefit plan chf million chf million define benefit plan fund status balance sheet position chf chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability overall funding status ifrs basis group fund define benefit plan increase compare start year come plan switzerland increase discount rate partially offset decrease fair value plan asset end addition plan asset define benefit obligation fund plan increase chf billion follow plan change switzerland fund status pension fund monitor local pension fund governance body closely review group level total cash outflow group define benefit plan chf billion compare chf billion high additional contribution pay group pension plan unfunded plan mainly group german affiliate fully reserve pension obligation self finance local affiliate operation unfunded liability plan decrease mainly high discount rate germany detail group pension postemployment benefit give note annual financial statement roche finance report roche group financial review roche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group consist roche healthcare company total shareholder return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate cer roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group chf term cer healthcare sector outperform world equity market characterise increase volatility second half year swiss market index smi post loss performance mix relative major global index smi underperform major index outperform european index roche share performance continue impact uncertainty impact biosimilar concern pricing reform despite positive news flow year strong latestage pipeline peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream datum roche peer index rebase january peer index convert swiss franc daily actual exchange rate currency fluctuation influence representation relative performance roche versus peer index propose dividend board director propose increase dividend chf share nonvoting equity security chf approval annual general meeting nd consecutive increase dividend dividend proposal approve shareholder dividend payment total share nonvoting equity security chf billion chf billion result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page roche finance report financial review roche group information share nonvoting equity security change chf chf chf eps basic eps diluted core ep basic core ep diluted equity attributable roche shareholder share dividend share detail refer note annual financial statement payout ratio calculate dividend share divide core earning share debt debt redemption follow redemption date june eur billion bond date september chf billion bond date september chf billion bond debt issuance follow issuance september group issue usd million bond september usd million bond september september group issue chf million bond september chf million bond september transaction describe note annual financial statement maturity schedule group bond note outstanding december show table bond note nominal amount december contractual maturity dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf total total translate december exchange rate proceed bond note eur million swap dollar consolidated result bond note economic characteristic equivalent dollardenominate bond note group plan meet debt obligation exist liquid fund cash generate business operation free cash flow chf billion include cash generate operation payment interest tax shortterm financing requirement group commercial paper program issue usd billion unsecured commercial paper note commit credit line usd billion available backstop line commercial paper note total usd billion outstanding december usd billion longerterm financing group maintain strong longterm investmentgrade credit rating aa standard poor aa moodys facilitate efficient access international capital market information group debt give note annual financial statement roche finance report roche group financial review financial risk december group net debt position chf billion chf billion financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security chf total chf total cash cash equivalent money market instrument debt security equity security total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group chf billion cash fix income marketable security remain strong invest aaaa range group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position group trade receivables chf billion begin financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country december trade receivables eur billion chf billion public customer country decrease compare december euro term group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action group trade receivable balance southern europe decrease euro term liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year roche enjoy strong longterm investmentgrade credit rating aa standard poor aa moodys time roche rate high available shortterm rating agency february moodys upgrade roche rating aa event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market group commit credit line financial institution total usd billion available backstop line commercial paper program december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price group var remain stable interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity group use interest rate derivative manage interest raterelate exposure financial result information financial risk management financial risk var methodology include note annual financial statement roche finance report financial review roche group international financial reporting standard roche group international financial reporting standard ifrs report consolidated result group implement ifrs financial instrument ifrs revenue contract customer include consequential amendment standard group implement minor amendment exist standard interpretation material impact group overall result financial position new revise standard apply ifrs financial instrument group implement new standard effective january apply exemption retrospective application classification measurement requirement include impairment mean comparative result restate standard deal classification recognition measurement include impairment financial instrument impairment financial asset include trade lease receivables introduce new hedge accounting model ifrs revenue contract customer group implement new standard effective january apply retrospective method transition new standard change amount revenue recognise restatement comparative result necessary new standard contain new set principle recognise measure revenue new requirement relate presentation core principle framework revenue recognise dependent transfer promise good service customer reflect consideration receive exchange good service ifrs business combination october international accounting standard board issue amendment ifrs business combination amendment clarify definition business add concentration test aid assessment transaction represent business combination simply substance purchase single asset group similar asset amendment mandatory early adopt effect amendment particularly applicable acquisition carry roche group value acquire company consist right single product technology effective january group early implement amendment prospective application restatement comparative period information reassessment cashgenerating unit allocate goodwill pharmaceutical division detailed section impairment goodwill intangible asset result impairment entry record align historic transaction transaction onwards use revise ifrs definition business result amendment ifrs acquisition ignyta reassess account asset acquisition annual financial statement business combination disclose interim financial statement lead decrease goodwill chf billion decrease intangible asset chf billion decrease defer tax liability chf billion apart new standard material impact group overall result financial position result implement ifrs group presentational change income statement include subtotal revenue create new note revenue note note annual financial statement detail matter new revise standard apply ifrs lease group implement new standard effective january apply cumulative catchup method option transition mean comparative result restate new standard apply main impact new standard bring operating lease onbalance sheet group currently anticipate new standard result carry value lease asset increase approximately chf billion lease liability increase similar date implementation application new standard result currently report operating lease cost record interest expense give lease involve prevail low interest rate environment group currently expect effect material note annual financial statement detail roche finance report roche group roche group consolidate financial statement roche group consolidate financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group consolidate financial statement roche group roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidate financial statement roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income oci remeasurement define benefit plan fair value change equity investment fair value oci na item reclassify income statement availableforsale investment na fair value change debt security fair value oci na cash flow hedge currency translation foreign operation item reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total statement comprehensive income adjust reflect presentational change require result implement ifrs financial instrument describe note roche finance report roche group consolidate financial statement roche group roche group consolidate balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset defer tax asset define benefit plan asset noncurrent asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer tax liability define benefit plan liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity roche finance report roche group roche group consolidate financial statement roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease net work capital payment define benefit plan utilisation provision disposal product operate cash flow income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination asset acquisition divestment subsidiary interest dividend receive sale equity security debt security purchase equity security debt security sale purchase money market instrument time account month net invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement change ownership interest subsidiary equity contribution noncontrolle interest interest pay dividend pay equitysettle equity compensation plan net transaction equity financing cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche finance report roche group consolidate financial statement roche group roche group consolidate statement change equity millions chf non share retain fair value hedge translation control total capital earning reserve reserve reserve total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december year end december january implementation ifrs financial instrument january revise net income recognise income statement net change fair value financial asset fair value oci cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change ownership interest subsidiary change noncontrolle interest equity contribution noncontrolle interest december equity january revise follow implementation ifrs financial instrument describe note addition statement change equity adjust reflect presentational change require implementation new standard roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement general accounting principle basis preparation consolidate financial statement annual financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention item require account fair value approve issue board director january subject approval annual general meeting shareholder march financial statement annual financial statement roche holding ltd company register switzerland subsidiary group group significant accounting policy change accounting policy disclose note key accounting judgement estimate assumption preparation annual financial statement require management judgement estimate assumption affect report amount revenue expense asset liability contingent amount actual outcome differ management estimate estimate underlying assumption review ongoing basis base historical experience factor revision estimate recognise period estimate revise follow consider key accounting judgement estimate assumption believe appropriate base currently available information revenue nature group business sale transaction simple structure consist performance obligation satisfy different time contract enter diagnostic division typically include performance obligation instrument include provide leasing arrangement reagent consumable service instrument sell cash sale transaction discount price instrument provide operating lease arrangement entire lease revenue variable subject subsequent reagent sale sale net discount base estimate relate obligation include standalone selling price fair value require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise outlicense agreement entered obligation include commitment conduct research latestage development regulatory approval comarketing manufacturing settle combination upfront payment milestone payment license fee reimbursement service provide consider commitment single performance obligation separate one scope ifrs revenue contract customer straightforward require judgement depend conclusion result revenue calculate inception recognise spread term long performance obligation sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount earn claim relate sale december group chf million provision accrual expect sale return chargeback rebate include medicaid similar rebate country provision accrual relate pharmaceutical business amount chf million chf million associate expect sale return estimate consideration historical experience current contractual statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust effect sale earning period adjustment business combination group initially recognise fair value identifiable asset acquire liability assume non control interest consideration transfer business combination management judgement particularly involve assessment net asset acquire constitute business recognition fair value measurement roche finance report note roche group consolidate financial statement roche group intellectual property inventory contingent liability contingent consideration make assessment management consider underlie economic substance item concern addition contractual term management apply consider appropriate optional concentration test set amendment ifrs business combination publish october aid assessment transaction represent business combination simply substance purchase single asset group similar asset impairment property plant equipment goodwill intangible asset december group chf million property plant equipment note chf million goodwill note chf million intangible asset note goodwill intangible asset available use review annually impairment property plant equipment intangible asset use assess impairment trigger event provide evidence asset impair assess impairment exist estimate expect future cash flow actual outcome vary significantly estimate factor change discount rate plan use building machinery equipment closure facility presence competition technical obsolescence lowerthananticipate product sale lead short useful life impairment impairment financial asset december group chf million allowance doubtful account trade lease receivable note allowance doubtful account base assumption risk default expect loss rate group use judgement make assumption select input calculation allowance doubtful account base company past experience exist market condition forwardlooke estimate end reporting period pension postemployment benefit group operate number define benefit plan fair value recognise plan asset liability base statistical actuarial calculation measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption december present value group define benefit obligation chf million note actuarial assumption differ materially actual result change market economic condition long short lifespan participant change factor assess difference impact define benefit plan asset liability recognise balance sheet future period legal provision group provide anticipated legal settlement cost probable outflow resource reliably estimate reliable estimate provision record contingent liability disclose material december group chf million legal provision status significant legal case disclose note estimate consider specific circumstance legal case relevant legal advice inherently judgemental highly complex nature legal case estimate change substantially time new fact emerge legal case progress environmental provision group provide anticipate environmental remediation cost probable outflow resource reasonably estimate december group chf million environmental provision note environmental provision consist primarily cost fully clean refurbish contaminate site include landfill treat contain contamination certain site estimate inherently judgemental uncertainty relate detection previously unknown contamination method extent remediation percentage problematic material attributable group remediation site financial capability potentially responsible party estimate change substantially time new fact emerge environmental remediation progress contingent consideration provision group make provision estimate fair value contingent consideration arrangement arise business combination december group chf million contingent consideration provision note total potential payment contingent consideration arrangement business combination chf million note estimate amount provide expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario discount net present value estimate change substantially time new fact emerge scenario develop income taxis december group current income tax net liability chf million defer tax net asset chf million note significant estimate require determine current defer tax asset liability estimate base interpretation exist tax law regulation tax position uncertain accrual record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience factor impact current defer taxis include change tax law regulation rate change interpretation exist tax law regulation future level research development spending change pretax earning roche finance report roche group note roche group consolidated financial statement lease treatment leasing transaction mainly determine lease consider operating finance lease making assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment consolidation group periodically undertake transaction involve obtain control significant influence company transaction include equity acquisition asset purchase alliance agreement case management make assessment group control significant influence company consolidated subsidiary account associate company make assessment management consider underlie economic substance transaction addition contractual term operate segment information group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include corporate executive committee global group function communication human resource finance include treasury taxis legal safety environmental service subdivisional information present roche pharmaceutical chugai operate segment pharmaceutical division divisional information millions chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination asset acquisition addition property plant equipment addition intangible asset total research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense roche finance report note roche group consolidate financial statement roche group pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result operate profit elimination result division operate profit capital expenditure business combination asset acquisition addition property plant equipment addition intangible asset total research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense net operating asset millions chf asset liability net asset december pharmaceutical diagnostic corporate total operating nonoperating group net operating asset pharmaceutical subdivisional information million chf asset liability net asset december roche pharmaceutical chugai elimination division pharmaceutical division roche finance report roche group note roche group consolidate financial statement information geographical area millions chf revenue external customer noncurrent asset royaltie property plant goodwill sale operate income equipment intangible asset switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue major customer total national wholesale distributor represent approximately group revenue national wholesale distributor mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenue pharmaceutical operating segment residual diagnostic segment roche finance report note roche group consolidate financial statement roche group revenue disaggregate revenue information disaggregation revenue millions chf revenue revenue contract revenue contract revenue customer source total customer source total pharmaceutical division sale therapeutic area oncology immunology neuroscience ophthalmology infectious disease therapeutic area sale royalty income income outlicense agreement income disposal product royalty operate income diagnostic division sale business area centralise point care solution diabetes care molecular diagnostic tissue diagnostic sale royalty income income outlicense agreement income disposal product royalty operating income total revenue source primarily relate lease revenue collaboration income counterparty consider customer income profitshare arrangement roche finance report roche group note roche group consolidate financial statement grosstonet sale reconciliation pharmaceutical division grosstonet sale reconciliation pharmaceutical division show table company diagnostic division similar reconciling item low amount pharmaceutical division sale grosstonet reconciliation million chf gross sale government regulatory mandatory price reduction contractual price reduction cash discount customer return reserve net sale government regulatory mandatory price reduction consist mandatory price reduction major element b drug discount program medicaid plan total usd billion equivalent chf billion usd billion equivalent chf billion contractual price reduction include rebate chargeback result contractual agreement primarily volumebase performancebase cash discount include credit offer wholesaler remit payment purchase contractually define incentive period customer return reserve allowance establish expect product return sale reduction expect withhold customer settlement contractual price reduction cash discount record balance sheet deduction trade receivable note sale reduction separately payable customer governmental health authority healthcare regulatory authority record balance sheet accrue liability note provision sale return record balance sheet provision note contract balance receivables millions chf account receivable current receivables contract customer noncurrent receivables contract customer total receivable current receivable mainly include royalty licensing receivable december total receivable include lease receivables consider receivables contract customer contract asset millions chf accrue income total contract asset roche finance report note roche group consolidate financial statement roche group contract liability millions chf defer income noncurrent defer income current total contract liability movement contract liability millions chf january business combination revenue recognise include contract liability balance begin year increase cash receive receivable exclude amount recognise revenue year divestment subsidiary currency translation effect december revenue recognise relation performance obligation satisfy previous year increase revenue recognise chf million increase chf million relate performance obligation satisfy previous period mainly adjustment sale deduction provision accrual expect sale return chargeback allowance respect previous year remain performance obligation partially unsatisfie longterm contract remain performance obligation partially unsatisfie longterm contract include defer income relate amount group expect receive good service transfer customer exist noncancellable enforceable contract mainly associate contract diagnostic division minimum purchase commitment related reagent consumable previously sell instrument monitor maintenance service contract original duration year group elect practical expedient disclose transaction price remain performance obligation end report period point time group expect recognise sale transaction price allocate contract partially unsatisfie performance obligation millions chf contract liability hold contract liability hold total thereof expect recognise revenue year year year total roche finance report roche group note roche group consolidate financial statement net financial expense transition ifrs note group elect restate comparative information result information provide current period ifrs basis comparative information ias basis financing cost millions chf interest expense amortisation debt discount net gain loss redemption repurchase bond note discount unwind net interest cost define benefit plan total financing cost financial income expense millions chf net gain loss sale equity security ias na dividend income availableforsale equity security ias na writedown impairment equity security ias na net gain loss equity investment security fair value profit loss ifrs na dividend income equity investment security fair value profit loss ifrs na dividend income equity investment security fair value oci ifrs na net income equity security interest income availableforsale debt security amortise cost ias na net gain loss sale debt security availableforsale security amortise cost ias na interest income fair value oci debt security amortise cost ifrs na net gain loss sale debt security fair value oci ifrs na net interest income income debt security net foreign exchange gain loss net gain loss foreign currency derivative foreign exchange gain loss gain loss net monetary position hyperinflationary economy net financial income expense associate total financial income expense financial income expense adjust reflect presentational change require result implement ifrs financial instrument describe note roche finance report note roche group consolidate financial statement roche group net financial expense million chf financing cost financial income expense net financial expense financial result treasury management financial result pension management associate net financial expense hyperinflationary economy july group consider argentina hyperinflationary economy context ias financial report hyperinflationary economy cumulative inflation index year exceed measure national wholesaler price index sistema de ndice de precios mayorista accordingly group review reporting affiliate argentina necessary restate line ia potential adjustment result application ias significant impact group operate result balance sheet adjustment record gain loss net monetary position loss chf million result loss purchasing power positive net monetary position group argentinian affiliate income taxis income tax expense millions chf current income taxis defer taxis total income tax expense group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate group average expect tax rate decrease largely decrease federal tax rate enact december effective january group effective tax rate decrease main driver decrease impact tax reform lower average expect tax rate mention addition tax reform transitional impact result initial estimate effect defer tax balance tax rate change result expense chf million increase group effective tax rate trueup adjustment transitional effect include result income chf million roche finance report roche group note roche group consolidate financial statement group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development tax credit deduction state tax impact tax unremitted earning transitional effect change tax rate prior year difference group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity chf million chf million income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately chf million chf million record tax effect comprehensive income millions chf pretax aftertax pretax aftertax tax tax remeasurement define benefit plan availableforsale investment ias na na na equity investment fair value oci ifrs na na na debt security fair value oci ifrs na na na cash flow hedge currency translation foreign operation comprehensive income income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer taxis asset liability net defer tax asset liabilitie current income tax liability include accrual uncertain tax position current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay business combination charge credit income statement charge credit equity equity compensation plan transaction shareholder currency translation effect movement net current income tax asset liability december roche finance report note roche group consolidate financial statement roche group defer taxis movement recognise net asset liability millions chf property define plant intangible benefit temporary equipment asset plan difference total year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december year end december january implementation ifrs financial instrument january revise business combination asset acquisition charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december defer tax net asset temporary difference mainly relate accrue liability provision unrealise profit inventory defer tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable chf tax rate chf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer tax liability establish withholding tax taxis payable remittance earning foreign subsidiary amount currently regard permanently reinveste purpose financial statement total unremitted earning group regard permanently reinveste purpose financial statement chf billion december chf billion roche finance report roche group note roche group consolidate financial statement merger acquisition group implement amendment ifrs business combination issue october amendment clarify definition business effect amendment particularly applicable acquisition carry group value acquire company largely consist right single product technology transaction account asset acquisition business combination note expand rename merger acquisition include transaction account business combination asset acquisition asset acquisition acquisition legal entity qualify business combination ifrs cash consideration pay asset acquisition transaction date subsequent additional contingent payment achievement performancerelate development milestone present line asset acquisition disclose separately subsequent consideration performancerelate development milestone transaction treat asset acquisition recognise intangible asset specific milestone achieve previously intangible asset acquire asset acquisition include line item purchase intangible asset statement cash flow addition note intangible asset result amendment ifrs note acquisition ignyta inc reassess account asset acquisition annual financial statement business combination disclose interim financial statement lead decrease goodwill chf million decrease intangible asset chf million decrease defer tax liability chf million business combination flatiron health inc april group acquire control interest flatiron health inc flatiron health privately own company base new york city flatiron health market leader curation development realworld evidence cancer research oncologyspecific electronic health record software flatiron health report pharmaceutical division total consideration usd million pay cash identifiable asset acquire liability assume set table business combination net asset acquire millions chf flatiron health intangible asset product intangible use marketing intangible use defer tax asset cash cash equivalent defer tax liability net asset liability net identifiable asset fair value previously hold interest goodwill total consideration cash total consideration fair value flatiron health technology platform determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate flatiron health valuation perform independent valuer flatiron health account receivable comprise gross contractual amount chf million expect collectable date acquisition goodwill represent value accelerate progress datadriven personalise healthcare cancer advance use realworld evidence set new industry standard oncology research development represent control premium acquire work force expect synergy goodwill expect deductible income tax purpose roche finance report note roche group consolidate financial statement roche group group recognise financial gain chf million fair valuing interest flatiron health hold group prior transaction gain include statement change equity line item net change fair value financial asset fair value oci transfer retain earning obtain control directly attributable transaction cost chf million report pharmaceutical operating segment general administration expense month december flatiron health contribute revenue chf million net loss tax chf million result report pharmaceutical division group acquisition occur january management estimate flatiron health contributed revenue chf million net loss tax chf million information provide illustrative purpose necessarily indicative result combine group occur flatiron health actually acquire beginning year indicative future result combine group business combination mysugr gmbh june group acquire control interest mysugr gmbh mysugr private company base vienna austria mysugr report diagnostic operating segment diabete care business total cash consideration eur million viewics inc november group acquire control interest viewic inc viewic privately own company base san jose california viewic report diagnostic operating segment total consideration usd million usd million pay cash usd million defer consideration pay period date control usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million identifiable asset acquire liability assume set table business combination net asset acquire millions chf mysugr viewic total intangible asset product intangible use marketing intangible use cash cash equivalent defer tax liability net asset liability net identifiable asset fair value previously hold interest goodwill total consideration cash defer consideration contingent consideration total consideration fair value product intangible asset mysugr determine replacement cost method fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate mysugr viewic valuation perform independent valuer goodwill represent control premium acquire work force synergy expect integrate acquire company group exist business goodwill expect deductible income tax purpose group recognise financial gain chf million chf million respectively fair valuing interest mysugr interest viewic hold group prior transaction gain include financial income expense roche finance report roche group note roche group consolidate financial statement directly attributable transaction cost chf million report diagnostic operating segment general administration expense impact mysugr viewic acquisition result diagnostic division group material cash flow business combination business combination net cash outflow millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay deferred consideration pay contingent consideration pay cash acquire company transaction cost na na na total net cash outflow directly attributable transaction cost business combination amount chf million include cash flow operating activity asset acquisition ignyta inc february group acquire control interest ignyta inc ignyta publicly own company base san diego california list nasdaq acquisition group obtain right ignytas lead product candidate entrectinib orally bioavailable cnsactive tyrosine kinase inhibitor patient tumour harbour ros ntrk fusion ignyta report pharmaceutical division total consideration usd million pay cash acquisition september group acquire control interest tusk therapeutics ltd tusk private company base stevenage united kingdom tusk develop antibody novel mode action aim deplete regulatory tcell suppress immune response include cancer cell tusk report pharmaceutical division november group acquire control interest jecure therapeutics inc jecure privately own company base san diego california acquisition group obtain right jecure preclinical portfolio nlrp inhibitors jecure report pharmaceutical division total cash consideration pay acquisition date acquisition chf million additional contingent payment base achievement performancerelate milestone asset acquisition net asset acquire millions chf ignyta acquisition total intangible asset product intangible available use defer tax asset cash cash equivalent net asset liability net identifiable asset cash total cash consideration roche finance report note roche group consolidate financial statement roche group cash flow asset acquisition asset acquisition net cash outflow millions chf pharmaceutical diagnostic total cash consideration pay cash acquire company total net cash outflow directly attributable transaction cost acquisition business combination amount chf million include cash flow operating activity foundation medicine transaction april group acquire control interest foundation medicine inc fmi treat fully consolidate subsidiary group date common stock fmi publicly trade list nasdaq stock code fmi december groups interest fmi june group enter merger agreement fmi acquire outstanding share fmis common stock own group price usd share cash merger agreement approve board roche special committee independent director fmi board director tender offer launch july july transaction closed fmi own subsidiary group account equity transaction cash consideration purchase public share include share issuable fmis outstanding stock incentive plan payment relate fee expense amount usd billion set table amount record equity change ownership interest subsidiary foundation medicine transaction usd million chf million purchase publicly hold share settlement outstanding stock option vest restrict stock award directly attributable transaction cost total cash consideration income tax effect change ownership interest subsidiary roche finance report roche group note roche group consolidate financial statement global restructuring plan group continue implementation resource flexibility plan initiate pharmaceutical division address future challenge include biosimilar competition focus area plan include biologic manufacturing commercial operation product developmentstrategy group continue implementation major global restructuring plan initiate prior year notably strategic realignment pharmaceutical division manufacturing network programme address longterm strategy diagnostic division global restructuring plan cost incur millions chf diagnostic site consolidation plan total year end december global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost year end december global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost include strategy plan diagnostic division include pharmaceutical division strategic realignment manufacture network resource flexibility biologic manufacturing network include plan outsource function share service centre external provider resource flexibility pharmaceutical division commercial operation global product developmentstrategy organisation diagnostic division strategy plan diagnostic division incur cost chf million mainly employeerelate matter chf million cost chf million include divestment subsidiary germany cost relate reorganisation molecular diagnostic business chf million spend small plan division chf million chf million roche finance report note roche group consolidate financial statement roche group site consolidation cost pharmaceutical division strategic realignment manufacturing network chf million chf million mainly relate exit manufacturing site clarecastle ireland resource flexibility biologic manufacturing network incur cost chf million mainly relate asset impairment severance cost chf million integration cost follow ignyta acquisition chf million global restructuring plan resource flexibility initiative pharmaceutical division incur cost chf million chf million mainly employeerelate major item chf million plan outsource share service centre external provider chf million plan include plan total chf million chf million global restructuring plan summary cost incur millions chf employeerelate cost termination cost define benefit plan employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment gain loss disposal property plant equipment site closure cost total site closure cost divestment product business gain loss divestment subsidiary gain loss divestment product business total cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost roche finance report roche group note roche group consolidate financial statement global restructuring plan classification cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total royalty operating income pharmaceutical diagnostic cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic general administration pharmaceutical diagnostic corporate total total operating segment roche pharmaceutical chugai diagnostic corporate total roche finance report note roche group consolidate financial statement roche group property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january addition disposal divestment subsidiary transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january business combination addition disposal divestment subsidiary transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value classification impairment property plant equipment million chf cost sale marketing distribution research development general administration total impairment charge impairment charge property plant equipment mainly relate global restructuring plan note reimbursement receive insurance company respect impairment property plant equipment borrowing cost capitalise property plant equipment roche finance report roche group note roche group consolidate financial statement genentech property purchase option exercise genentech enter master lease agreement mla slough ssf llc slough subsequently acquire health care property lease property adjacent genentechs south san francisco site develop slough development include total building construction complete time genentech fully occupy property property lease extension option november genentech exercise purchase option contain mla acquire building land december group record addition land building land improvement correspond liability cash outflow group reclassify finance lease accounting balance previously apply building november close payment usd million final closing payment usd million june note leasing arrangement group lessee finance lease december capitalise cost property plant equipment finance lease chf million chf million net book value asset chf million chf million carrying value leasing obligation chf million chf million report debt note finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value minimum lease payment payment year year year total future finance charge total future minimum lease payment undiscounte operating lease group company party number operating lease mainly property rental motor vehicle arrangement impose significant restriction group total operating lease rental expense chf million chf million operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment roche finance report note roche group consolidate financial statement roche group leasing arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method finance lease future minimum lease receipt noncancellable lease millions chf present value minimum gross investment lease lease receipt year year year total unearned finance income na na unguaranteed residual value na na net investment lease accumulate allowance uncollectible minimum lease payment nil chf million operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straightline basis december machinery equipment original cost chf billion chf billion net book value chf billion chf billion lease party operate lease future minimum lease receipt noncancellable lease millions chf year year year total minimum receipt implementation ifrs lease group implement new standard effective january ifrs replace exist lease guidance include ias lease set principle recognition measurement lease note detail capital commitment group noncancellable capital commitment purchase construction property plant equipment totalling chf billion chf billion roche finance report roche group note roche group consolidated financial statement goodwill goodwill movement carry value asset millions chf january cost accumulate impairment net book value year end december january business combination divestment subsidiary impairment charge currency translation effect december cost accumulate impairment net book value allocate follow cashgenerating unit roche pharmaceutical foundation medicine pharmaceutical product transaction chugai total pharmaceutical division diabetes care centralise point care solution molecular diagnostic tissue diagnostic sequence divisional goodwill total diagnostic division cashgenerating unit allocate goodwill pharmaceutical division group comprehensive reassessment cashgenerating unit allocate goodwill pharmaceutical division reassessment light follow factor ongoing business transformation pharmaceutical division acquisition flatiron health effective april transaction fully acquire foundation medicine effective july early adoption amendment ifrs business combination issue october amendment clarify definition business transaction represent substance purchase business single asset group similar asset roche finance report note roche group consolidate financial statement roche group conclusion reassessment follow roche pharmaceutical operating segment goodwill arise broad type transaction strategic transaction transformative effect division technology transaction acquire technology range area application product transaction acquire product typically limited synergistic benefit outside immediate product therapeutic area cashgenerating unit goodwill arise strategic transaction roche pharmaceutical operating segment cashgenerating unit goodwill arise technology transaction roche pharmaceutical operating segment acquire technology permanently cease operate treat disposal business case goodwill deem dispose fully impair cashgenerating unit goodwill arise product transaction small identifiable group asset relate revenue relate cost arise development commercialisation product question synergistic benefit product therapeutic area revenue cost correspond asset product take account acquire product permanently cease generate economic benefit treat disposal business case goodwill deem dispose fully impair chugai remain separate operating segment group financial reporting remain separate cashgenerating unit goodwill allocate base reassessment group allocate remain goodwill roche pharmaceutical operating segment list basis reallocation historical amount goodwill arise individual transaction strategic transaction consist genentech foundation medicine flatiron health technology transaction consist therapeutic human polyclonal dutalys santaris product transaction consist glycart tanox intermune trophos diagnostic division division business area sequence business cashgenerating unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division goodwill arise viewic acquisition monitor divisional level recoverable impairment testing base value use impairment charge pharmaceutical division assessment potential impairment goodwill pharmaceutical division carry cash generating unit set impairment charge total chf million record pharmaceutical division intermune acquisition charge chf million record writeoff goodwill intermune acquisition main product acquire original transaction intermune medicine idiopathic pulmonary fibrosis esbriet idiopathic pulmonary fibrosis progressive disease cause scar lung survival rate year diagnosis group record impairment charge chf million partial impairment esbriet product intangible use main factor lead decrease forecast cash flow relative previous year longterm forecast reduction sale expectation group review asset liability acquire intermune transaction detail include initial valuation report purpose acquisition account subsequent integration process conclusion review apart intangible asset represent acquire right esbriet relate defer taxation liability asset liability record group balance sheet revenue stream part acquire company synergistic benefit continue operation roche group roche finance report roche group note roche group consolidate financial statement group required assessment potential impairment goodwill arise intermune acquisition cashgenerating unit identifiable group asset relate revenue relate cost arise development commercialisation esbriet group regular process value use intangible asset represent acquire right esbriet test impairment note second step goodwill intermune acquisition test impairment conclusion impairment test substance remain value group intermune acquisition estimate chf million solely relate acquire right esbriet report group balance sheet product intangible asset use previously record impairment esbriet product intangible asset use partially reverse income chf million record asset concern write estimate recoverable value chf million main factor lead increase forecast cash flow relative previous year longterm forecast improvement sale expectation intangible asset continue amortise remain estimate useful life year note impairment chf million record goodwill intermune acquisition revenue relate cost arise development commercialisation esbriet fully utilise impairment testing process support value use esbriet product intangible asset use surplus esbriet revenue support carry value goodwill synergistic benefit product therapeutic area accordingly separable recoverable value goodwill estimate zero fully impair trophos acquisition charge chf million record writeoff goodwill trophos acquisition main product acquire original transaction trophos proprietary screening platformgenerate olesoxime tro develop spinal muscular atrophy sma rare debilitate genetic neuromuscular disease commonly diagnose child group decide stop development compound potential future revenue support carry value goodwill synergistic benefit product franchise accordingly intangible asset relate product fully impair note goodwill deem dispose fully impair diagnostic division charge chf million record centralised point care business area write goodwill cmi acquisition group decide change commercialisation strategy diagnostic instrument haematology testing lead impairment product intangible use acquire cmi acquisition note goodwill deem dispose fully impair impairment charge impairment charge total chf million record relate charge chf million diagnostic division writeoff sequence business goodwill factor lead impairment decrease forecast cash flow relative previous year longterm forecast change assumption market penetration pricing reimbursement ii revise time market single molecule sequence technology addition impairment charge chf million record sequence business product intangible use acquire ariosa acquisition note charge chf million pharmaceutical division writeoff goodwill relate seragon acquisition decision stop development backup compound acquire roche finance report note roche group consolidate financial statement roche group value use value use calculate discount expect cash flow approach posttax discount rate apply project risk adjust posttax cash flow terminal value discount rate group weight average cost capital cashgenerating unit integrate operation large part group derive capital asset pricing model data capital market include government twentyyear bond assess value use cash flow projection base recent longterm forecast approve management longterm forecast include management late estimate sale volume pricing production operating cost assume significant change organisation key assumption calculation period cash flow projection include longterm forecast terminal value growth rate discount rate key assumption valueinuse calculation period terminal period terminal cash flow value discount rate cash flow value discount rate projection growth rate tax projection growth rate tax pharmaceutical division year na year na diagnostic division year year cashgenerating unit terminal value growth respective rate exceed longterm project growth rate relevant market fair value cost disposal goodwill arise chugai acquisition fair value cost disposal determined reference publicly quote price chugai share sensitivity analysis management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount rate combine decrease forecast cash flow chugai decrease publicly quote share price result sensitivity analysis demonstrate change key assumption cause carry value goodwill exceed recoverable amount december roche finance report roche group note roche group consolidate financial statement intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january business combination addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group year end december january business combination asset acquisition addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group roche finance report note roche group consolidate financial statement roche group significant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use esbriet intermune acquisition roche pharmaceutical year flatiron health acquisition roche pharmaceutical year shionogi licence transaction roche pharmaceutical year foundation medicine acquisition roche pharmaceutical year kapa acquisition diagnostic year iquum acquisition diagnostic year product intangible available use entrectinib ignyta acquisition roche pharmaceutical na biontech licence transaction roche pharmaceutical na geneweave acquisition diagnostic na technology intangible use dutalys acquisition roche pharmaceutical year classification intangible asset amortisation impairment expense millions chf amortisation impairment cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic total internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful live intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination asset acquisition separate purchase december approximately project pharmaceutical division know decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project expect result commercialise product roche finance report roche group note roche group consolidate financial statement intangible asset impairment impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lowerthananticipate sale product capitalise right result shorten useful life impairment impairment charge pharmaceutical division impairment charge total chf million net impairment reversal record related charge chf million decision stop development different compound different alliance partner asset concern amortise fully write charge chf million decision stop development compound purchase separately asset concern amortise fully write charge chf million decision stop development compound acquire trophos acquisition asset concern amortise fully write charge chf million partial impairment compound purchase separately delay timeline asset concern amortise partially write charge chf million follow clinical datum assessment asset concern amortise fully write charge chf million impairment asset concern amortise fully write previously record impairment esbriet product intangible asset use partially reverse income chf million record asset concern write estimate recoverable value chf million main factor lead increase forecast cash flow relative previous year longterm forecast improvement sale expectation intangible asset continue amortise remain estimate useful life year goodwill impairment charge relate intermune acquisition discuss note diagnostic division impairment charge total chf million record relate charge chf million impairment intangible use available use related sequence business mainly acquire genia capp signature acquisition factor lead impairment change commercialisation strategy relate product change timeline future product development asset concern partly amortise partly amortise fully write charge chf million partial impairment sequence business product intangible use acquire ariosa acquisition factor leading impairment decrease forecast cash flow follow revise sale assumption asset concern amortise write estimate recoverable value chf million charge chf million impairment centralise point care solution product intangible use acquire cmi acquisition result decision change commercialisation strategy diagnostic instrument haematology testing asset concern amortise fully write impairment charge pharmaceutical division impairment charge total chf million record relate charge chf million partial impairment esbriet product intangible use acquire intermune acquisition asset concern write estimate recoverable value chf million main factor lead decrease forecast cash flow relative previous year longterm forecast reduction sale expectation intangible asset continue amortise remain estimate useful life year charge chf million launch competitor product compound acquire trophos acquisition asset concern amortise write estimate recoverable value chf million charge chf million decision stop development compound alliance partner follow assessment clinical nonclinical datum asset concern amortise fully write charge chf million decision stop development compound acquire dutaly acquisition asset concern amortise fully write charge chf million decision stop development compound acquire santaris acquisition follow clinical datum assessment asset concern amortise fully write charge chf million decision stop development compound different alliance partner asset concern amortise fully write charge chf million follow clinical datum assessment asset concern amortise fully write roche finance report note roche group consolidate financial statement roche group diagnostic division impairment charge total chf million record relate charge chf million partial impairment molecular diagnostic product intangible available use acquire geneweave acquisition factor lead partial impairment decrease forecast cash flow follow change timeline future product development pricing penetration rate update market size assumption asset concern amortise write estimate recoverable value chf million charge chf million partial impairment sequence business product intangible use acquire ariosa acquisition factor leading impairment decrease forecast cash flow follow revise assumption price penetration rate market dynamic asset concern amortise write estimate recoverable value chf million potential commitment alliance collaboration purchase agreement year group party inlicense similar arrangement alliance partner intangible asset purchase agreement party arrangement purchase agreement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration purchase agreement group current estimate future thirdparty commitment payment year set table figure undiscounte riskadjuste meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business potential future thirdparty collaboration purchase payment december millions chf pharmaceutical diagnostic group year year year total inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory inventory expense cost sale total chf billion chf billion inventory writedown year result expense chf million chf million roche finance report roche group note roche group consolidated financial statement account receivable account receivable millions chf trade receivables note receivable receivables allowance doubtful account chargeback allowance withhold settlement total account receivable allowance doubtful account movement recognise allowance millions chf january implementation ifrs financial instrument na january revise na additional allowance create unused amount reverse utilise year currency translation effect december bad debt expense record marketing distribution cost total chf million expense chf million marketable security transition ifrs note group elect restate comparative information result information provide current period ifrs basis comparative information ias basis marketable security millions chf ifrs ias ias equity security availableforsale ia na equity security fair value profit loss ifrs na na debt security availableforsale ia na debt security fair value oci ifrs na na money market instrument time account month availableforsale ia na money market instrument fair value oci ifrs na na time account month amortise cost ifrs na na total marketable security marketable security hold fund management purpose primarily denominate dollar euro swiss franc money market instrument contract mature year december roche finance report note roche group consolidate financial statement roche group debt security contract maturity million chf ifrs ias ias year year year total debt security cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent noncurrent asset transition ifrs note group elect restate comparative information result information provide current period ifrs basis comparative information ia basis noncurrent asset millions chf availableforsale investment hold fair value ia na availableforsale investment hold cost ias na equity investment fair value oci ifrs na na equity investment fair value profit loss ifrs na na loan receivable restrict cash receivables contract customer receivables total financial noncurrent asset longterm employee benefit asset total nonfinancial noncurrent asset associate total noncurrent asset equity investment designate fair value oci mainly investment private company pharmaceutical sector hold group strategic alliance effort equity investment classify availableforsale roche finance report roche group note roche group consolidate financial statement current asset current asset millions chf accrue interest income derivative financial instrument restrict cash cash collateral receivables receivables contract customer receivables total financial current asset prepaid expense accrue income taxis recoverable asset total nonfinancial current asset total current asset account payable account payable million chf trade payable taxis payable dividend payable payable total account payable roche finance report note roche group consolidate financial statement roche group noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability longterm liability mainly relate accrued employee benefit include genentech property purchase option exercise obligation pay june note current liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument cash collateral payable accrue chargeback allowance separately payable accrue royalty commission accrue liability total current liability december accrue liability include chf million shortterm genentech property purchase option exercise obligation pay june note roche finance report roche group note roche group consolidate financial statement provision contingent liability provision movement recognise liability millions chf contingent legal environmental restructure consideration provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration currency translation effect december current noncurrent december year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration asset acquisition divestment subsidiary currency translation effect december current noncurrent december expect outflow resource year year year year december chf million provision utilise chf million chf million chf million include cash flow operating activity chf million chf million include cash flow business combination payment deferred contingent consideration arrangement note roche finance report note roche group consolidate financial statement roche group legal provision legal provision consist number separate legal matter include claim arise trade group company nature amount timing outflow difficult predict regular review litigation matter management reassess provision record certain litigation matter base development litigation net increase provision chf million major element legal expense chf million net income chf million detail major legal case outstanding disclose environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict significant provision discount time value money material significant provision relate site nutley new jersey divest september estimate remediation cost landfill site near grenzach germany manufacturing operation close year ago estimate remediation cost manufacturing site clarecastle ireland expect cost environmental remediation clarecastle site matter reassess accordingly environmental provision increase chf million net net environmental expense chf million net expense chf million group procedure environmental protection include annual report page include action take group regard climate change notably group commitment reduce greenhouse gas emission restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain provision discount time value money material matter pharmaceutical division significant provision relate strategic realignment manufacture network resource flexibility plan address future challenge include biosimilar competition research development strategic alignment outsourcing function share service centre external provider diagnostic division significant provision associate programme address longterm strategy detail give note contingent consideration provision group party certain contingent consideration arrangement arise business combination significant provision discount average discount rate time value money material additional detail measurement main movement provision total potential payment arrangement provide note roche finance report roche group note roche group consolidate financial statement provision provision relate item show table exception employee provision time cash outflow nature uncertain provision millions chf employee provision sale return item total provision contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note pharmaceutical legal case december provision legal case pharmaceutical division chf million chf million provision record case settled mainly relate matter list accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation mdl district court middle district florida tampa division august mdl closed pendency mdl district court grant summary judgment favour hlr federal ibd case proceed affirm court appeal eleventh circuit action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county february superior court new jersey law division atlantic county hold eightday evidentiary hearing plaintiff expert testify accutane cause crohns disease february superior court bar plaintiff expert method meet requirement scientific reliability superior court enter order dismiss prejudice agreedupon list crohns disease case subject superior court february order july new jersey appellate division reverse order exclude plaintiff expert testify accutane cause crohns disease reinstate dismiss case find trial court wrongfully bar plaintiff expert witness hlr file petition review new jersey supreme court grant december august supreme court issue decision plaintiff expert testify accutane cause crohns disease supreme court reverse judgment new jersey appellate division conclude trial court properly exclude expert dismiss case allege accutane cause plaintiff crohns disease plaintiff appeal crohns disease case permanently dismiss roche finance report note roche group consolidate financial statement roche group superior court enter order grant summary judgment dismiss case file new jersey resident basis drug label adequate matter law july superior court grant hlrs motion summary judgment adequacy label post ingestion case jurisdiction superior court apply new jersey law jurisdiction grant hlrs motion dismiss approximately case alternative superior court apply home state law grant summary judgment jurisdiction deny jurisdiction resulted case dismiss july new jersey appellate division affirm dismissal case reinstate judgment case base strength hlrs warning hlr dismiss plaintiff file petition review new jersey supreme court grant december october supreme court issue decision case reverse judgment new jersey appellate division reinstate case basis drug label adequate matter law plaintiff appeal case permanently dismiss january october superior court enter order grant summary judgment dismiss case failure prove accutane proximately cause ulcerative colitis plaintiff appeal decision february march superior court new jersey law division atlantic county hold evidentiary hearing plaintiff expert testify accutane cause ulcerative colitis april superior court bar plaintiff expert method meet requirement scientific reliability superior court enter order dismiss ulcerative colitis case subject superior court april order plaintiff appeal decision oral argument expect december hlr defend pende action approximately case appeal case survive appeal additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive future trial result group continue defend vigorously remain personal injury case claim avastinlucentis investigation february italian antitrust authority agcm announce investigation determine roche genentech novartis enter agreement restrict competition italian market drug reference particular avastin market roche lucentis market novartis avastin lucentis different drug develop approve different therapeutic purpose contain different active pharmaceutical ingredient march agcm issue verdict allege roche novartis collude artificially differentiate avastin lucentis order foster sale lucentis italy agcm fine roche eur million novartis eur million roche appeal agcm verdict tribunale amministrativo regionale del lazio tar december tar uphold decision agcm roche strongly disagree verdict tar appeal consiglio di stato italian ministry health notify roche spa intention seek damage relate matter july roche pay eur million fine protest avoid additional penalty fee record expense general administration fine relate interest reimburse roche win case january european court justice render decision question refer european court justice consiglio di stato principle define decision consiglio di stato render final verdict case outcome matter determined time pdl inhibitor litigation july bristolmyers squibb co bms file lawsuit genentech inc genentech delaware bms allege genentech sale tecentriq infringe patent bms seek judgment favour find wilfulness monetary damage october genentech file answer counterclaim seek declaratory judgment invalidity patent trial date schedule outcome matter determined time average wholesale price litigation hlr roche laboratories inc rli approximately brand generic pharmaceutical company name defendant legal action relate price pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend awp action file state new jersey hlr rli vigorously defend trial date set outcome matter determine time roche finance report roche group note roche group consolidated financial statement boniva litigation hlr genentech roche affiliate collectively roche name defendant numerous legal action dismiss case canada relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw atypical femoral fracture december roche defend approximately action involve approximately plaintiff bring federal state court personal injury allegedly result use boniva case early discovery stage litigation individual trial result depend variety factor include unique particular case roche vigorously defend matter outcome matter determine time addition matter list currently provision record potential future obligation confirm occurrence nonoccurrence uncertain future event obligation measure sufficient reliability hemlibra emicizumab litigation baxalta inc baxalta gmbh baxalta subsidiary shire plc file patent infringement declaratory judgment patent infringement suit district court district delaware allege genentech chugai pharmaceutical co ltd chugai currently imminently manufacture use sell offer sale import hemlibra emicizumab infringe baxalta patent baxalta seek judgment infringement injunctive monetary relief attorney fee cost expense genentech serve complaint genentech response counterclaim complaint file june june chugai waive service september chugai file motion dismiss complaint lack personal jurisdiction december baxalta file request preliminary injunction genentech inhibitor patient subject injunction hearing hold district court district delaware june hearing baxalta withdraw request preliminary injunction inhibitor patient june baxalta submit new propose preliminary injunction order genentech permit sell hemlibra inhibitor patient noninhibitor patient currently hemlibra clinical trial select noninhibitor patient additional medically diagnose condition render factor viii therapy impracticable august district court rule baxalta deny request injunction september chugai dismiss case trial schedule september march case bring baxalta chugai japan tokyo district court rule favour chugai notably hemlibra infringe baxalta patent baxalta appeal decision november food drug administration fda approve hemlibra haemophilia inhibitor use october fda approve use hemlibra treatment noninhibitor patient population outcome matter determine time security litigation june class action file district court district new jersey roche holding ltd current officer lawsuit bring claim federal security law connection group public disclosure particular respect matter relate roche drug herceptin perjeta september district court dismiss case conclude mislead public disclosure subsequently plaintiff file second amend complaint group vigorously defend matter outcome matter determine time iraqi ministry health october f hoffmannla roche ltd fhlr hoffmannla roche inc hlr genentech certain pharmaceutical andor medical device company name defendant complaint file federal district court district columbia behalf servicemember relative allege kill injure iraq iraq lawsuit complaint allege defendant violate antiterrorism act state law provide fund terrorist organisation sale practice pursuant pharmaceutical andor medical device contract iraqi ministry health addition fhlr receive inquiry july department justice connection anticorruption investigation relate activity iraq include interaction iraqi government certain matter allege iraq lawsuit group vigorously defend matter outcome matter determined time arbitration chugai medical research council lifearc medical research council technology request arbitration chugai pharmaceutical co ltd arbitrator appoint august april united kingdom research innovation ukri establish successor title medical research council current claimants arbitration lifearc ukri sums seek chugai allege breach obligation collaboration agreement date august connection development humanise antihuman il receptor monoclonal antibody actemraroactemra claim chugai oblige pay royalty claimants pursuant collaboration agreement chugai consider claim merit chugai vigorously defend arbitration outcome matter determine time roche finance report note roche group consolidate financial statement roche group debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt change finance cash flow net gain loss redemption repurchase bond note amortisation debt discount financing cost business combination net foreign currency transaction gain loss currency translation effect change foreign exchange rate change fair value hedge instrument change december bond note commercial paper amount bank financial institution finance lease obligation borrowing total debt longterm debt shortterm debt total debt pledge group asset connection debt roche finance report roche group note roche group consolidate financial statement bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollar note fix rate note september principal usd billion isin usbc note september principal usd billion isin usba note september principal usd billion isin usbb note january principal usd billion isin usbm note september principal usd billion isin usbn na note september principal usd billion isin usbe na note november principal usd billion isin usbj na note principal usd billion isin usbk na note january principal usd billion isin usbl na note september principal usd billion isin usbp na note march principal usd billion outstanding usd billion isin usuan usau note november principal usd billion isin usbh na dollar note float rate note september principal usd billion isin usbd na note september principal usd billion isin usaz na euro medium term note programme fix rate note june principal eur billion isin xs na note march principal usd billion isin xs note march principal eur billion outstanding eur billion isin xs note february principal eur billion isin xs na note august principal gbp billion outstanding gbp billion isin xs na note february principal eur billion isin xs na swiss franc bond fix rate bond march principal chf billion isin ch na bond september principal chf billion isin ch bond september principal chf billion isin ch na bond september principal chf billion isin ch bond september principal chf billion isin ch bond september principal chf billion isin ch na bond march principal chf billion isin ch na bond september principal chf billion isin ch na genentech senior note senior note july principal usd billion outstanding usd billion isin usac na total bond note roche finance report note roche group consolidate financial statement roche group bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond pound sterling note total unamortised discount issuance bond note september group complete offer chf billion chf billion fix rate bond coupon respectively bond mature september september respectively bond list swiss exchange group receive chf million aggregate net proceed issuance sale fix rate bond september group complete offer usd billion usd billion fix rate note coupon respectively note mature september september respectively group receive chf million aggregate net proceed issuance sale fix rate note issuance bond note march group complete offer chf billion fix rate bond issue tranche chf million bond zero coupon mature september chf million bond coupon mature september chf million bond coupon mature march bond list swiss exchange group receive chf million aggregate net proceed issuance sale fix rate bond redemption repurchase bond note redemption euro note date june group redeem fix rate note principal eur billion cash outflow chf million plus accrue interest effective interest rate bond redemption swiss franc bond date september group redeem fix rate bond principal chf billion cash outflow chf million plus accrue interest effective interest rate bond date september group redeem bond zero coupon principal chf billion cash outflow chf million plus accrue interest effective interest rate bond roche finance report roche group note roche group consolidate financial statement redemption repurchase bond note redemption swiss franc bond date march group redeem fix rate bond principal chf billion cash outflow chf million plus accrue interest effective interest rate bond redemption dollar note date september group redeem fix rate note principal usd billion cash outflow chf million plus accrue interest effective interest rate note date september group redeem float rate note principal usd billion cash outflow chf million plus accrue interest effective interest rate note redemption pound sterling note november group complete tender offer repurchase gbp million fix rate note august cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note redemption euro note november group complete tender offer repurchase eur million fix rate note march cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note additional chf million gain recognise net gain loss redemption repurchase bond note come termination crosscurrency swap hedge tender portion euro note cash flow issuance redemption repurchase bond note cash inflow issuance bond note millions chf dollar note swiss franc bond total cash inflow issuance bond note cash outflow redemption repurchase bond note millions chf euro medium term note programme pound sterling note euro medium term note programme euro note dollar note swiss franc bond total cash outflow redemption repurchase bond note commercial paper roche holdings inc commercial paper program roche holdings inc establish commercial paper program issue usd billion unsecured commercial paper note guarantee roche holding ltd total commit credit line available backstop support commercial paper program usd billion december maturity note program exceed day date issuance december unsecured commercial paper note principal usd billion average interest rate outstanding roche finance report note roche group consolidate financial statement roche group movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december amount bank financial institution amount denominate currency average interest rate december amount outstanding chf million chf million year equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve retain share capital earning fair value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment subsidiary noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december entire transfer income statement report financial income expense roche finance report roche group note roche group consolidate financial statement change equity attributable roche shareholder millions chf reserve retain share capital earning fair value hedge translation total year end december january implementation ifrs financial instrument january revise net income recognise income statement financial asset fair value oci fair value gain loss equity investment fair value oci fair value gain loss take retain earning disposal equity investment fair value oci fair value gain loss debt security fair value oci fair value gain loss transfer income statement debt security fair value oci income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment subsidiary noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change ownership interest subsidiary change noncontrolle interest december b entire transfer income statement report financial income expense b cost hedging reserve relate eurusd crosscurrency swap include hedging reserve amount chf million net tax december equity attributable roche shareholder january revise follow implementation ifrs financial instrument describe note addition statement change equity adjust reflect presentational change require implementation new standard roche finance report note roche group consolidate financial statement roche group genentech transaction group complete purchase noncontrolle interest genentech effective march base international accounting standard separate financial statement ias consistent international financial reporting standard consolidated financial statement ifrs adopt group transaction account equity transaction consequence carrying consolidate equity group time reduce chf billion chf billion allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy share capital december authorise issue share capital roche holding ltd group parent company consist million share nominal value chf precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool describe note base information supply group novartis hold ag basel own participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend chf share nonvoting equity security chf respect business year distribution holder outstanding share nonvoting equity security total chf million chf million record retain earning board director propose dividend business year chf share nonvoting equity security approve result total distribution shareholder chf million subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security million million share nonvoting equity security total equity instrument record equity original purchase cost december fair value share chf million fair value nonvoting equity security chf billion equity instrument hold group potential conversion obligation arise group equity compensation plan note roche finance report roche group note roche group consolidate financial statement reserve fair value reserve december fair value reserve represent cumulative net change fair value financial asset fair value oci previously availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc subsidiary associate chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai consolidated subsidiary chugai fully consolidated subsidiary group base group interest chugai december roche relationship chugai found basic alliance licensing research collaboration agreement common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement accordance international financial reporting standard ifrs file quarterly basis tokyo stock exchange certain consolidation entry minor difference chugais standalone ifrs result result chugai consolidated roche group accordance ifrs chugai summarise financial information millions chf income statement sale royalty operating income total revenue operate profit balance sheet noncurrent asset current asset noncurrent liabilitie current liability total net asset cash flow cash flow operating activity cash flow invest activity cash flow financing activity dividend dividend distribute party hold chugai share total chf million chf million record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item roche finance report note roche group consolidate financial statement roche group roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche rest world umbrella right agreement exclude japan south korea sign revise amend restate rest world umbrella right agreement exclude japan south korea taiwan sign august agreement roche right refusal development marketing chugais development compound market outside japan exclude south korea taiwan agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area small molecule synthetic drug research biotechnologybase drug discovery foundation medicine april group acquire control interest foundation medicine inc fmi publicly own company base cambridge massachusetts enter investor right agreement research development collaboration agreement commercial collaboration agreement fmi treat fully consolidate subsidiary group date december group interest fmi common stock fmi publicly trade list nasdaq stock code fmi fmi prepare financial statement accordance gaap file quarterly basis sec certain consolidation entry difference fmis standalone gaap result result fmi consolidated roche group accordance ifrs june group enter merger agreement fmi acquire outstanding share fmis common stock own group price usd share cash tender offer launch july july transaction closed fmi own subsidiary group account equity transaction note dividend dividend distribute party hold fmi share roche finance report roche group note roche group consolidated financial statement associate senseonic hold inc senseonic treat associate group december group interest senseonic december group exclusive distributor senseonic eversense product solution major market outside opinion management give group potential exercise significant influence operation senseonic business common stock senseonic publicly trade list new york stock exchange nysemkt stock code sen senseonic prepare financial statement accordance gaap file quarterly basis sec group account senseonic equity method base senseonic financial statement publicly available group share senseonic result profit chf million include financial income expense note carry value group share senseonic net asset december asset chf million include noncurrent asset note divestment subsidiary divestment subsidiary november group sell wholly own subsidiary roche diagnostic solution gmbh berlin germany party total consideration eur million defer consideration november total loss divestment chf million report global restructuring cost diagnostic operating segment include general administration group receive defer consideration eur million sale subsidiary segrate site italy party divestment subsidiary february group sell wholly own subsidiary roche carolina inc florence party previously announce pharmaceutical division strategic realignment manufacturing network september group sell wholly own subsidiary segrate site italy party previously announce pharmaceutical division strategic realignment manufacture network total gain loss divestment show table gain loss divestment subsidiary millions chf cash consideration defer consideration total consideration property plant equipment goodwill cash cash equivalent provision net asset liability currency translation foreign operation transfer income statement total net asset dispose provision accrual residual obligation retain group gain loss divestment subsidiary cash flow divestment subsidiary millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration receive defer consideration receive cash divest company total net cash inflow roche finance report note roche group consolidate financial statement roche group noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement chugai noncontrolle interest total net income recognise income statement availableforsale investment ias na equity investment fair value oci ifrs na debt security fair value oci ifrs na cash flow hedge currency translation foreign operation remeasurement define benefit plan comprehensive income net tax total comprehensive income business combination dividend noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity change ownership interest subsidiary change noncontrolle interest equity contribution noncontrolle interest december chugai noncontrolle interest total noncontrolle interest roche finance report roche group note roche group consolidate financial statement employee benefit employee remuneration million chf wage salary social security cost define contribution plan operating expense define benefit plan equity compensation plan termination cost employee benefit employee remuneration include operating result net interest cost define benefit plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan define contribution plan define contribution plan fund payment employee group fund administer party group expense plan chf million chf million asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution group major define contribution plan roche k saving plan define benefit plan plan usually establish trust independent group fund payment group company employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource plan usually govern senior governing body board trustee typically compose employee employer representative funding plan determine local regulation independent actuarial valuation separate independent actuarial valuation prepare accordance requirement ias use group financial statement group major pension plan locate switzerland germany total account group define benefit obligation roche finance report note roche group consolidate financial statement roche group pension plan switzerland current pension arrangement employee switzerland plan govern swiss federal occupational old age survivor disability pension act bvg group pension plan administer separate legal foundation fund regular employee company contribution final benefit contributionbase certain minimum guarantee minimum guarantee swiss plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan underfunding remedie measure increase employee company contribution lower interest rate retirement account balance reduce prospective benefit suspension early withdrawal facility follow plan change employee profitshare plan mitarbeitergewinnbeteiligung long qualify define contribution plan define benefit plan result addition plan asset define benefit obligation approximately chf billion operating income chf million record past service cost plan change switzerland chf million record pharmaceutical division chf million diagnostic division chf million corporate past service income record general administration pension plan group major define benefit plan close new member new employee join define contribution plan large remain define benefit plan fund pension plan small unfunded supplementary retirement plan benefit base high average annual rate earning specify period length employment plan noncontributory employee group make periodic payment plan underfunding normally remedie additional company contribution payment group usd million usd million increase payment compare accelerated contribution benefit high tax deduction group enter annuity buyout agreement insurance company pay usd million plan asset settle define benefit obligation retire employee lead settlement loss usd million pension plan germany group major pension arrangement germany govern occupational pension act betravg plan unfunded group pay pension retire employee directly financial resource plan noncontributory employee benefit base final salary length employment plan close new member replace new plan fund regular employee company contribution administer contractual trust agreement final benefit contributionbase minimum guarantee minimum guarantee plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan pension plan rest world represent approximately group define benefit obligation consist number small plan country large pension plan chugai independently manage chugai main pension plan united kingdom chugai plan fully describe chugais ifrs financial statement uk pension plan fund regular employee company contribution benefit base final salary length employment plan close new member replace define contribution plan relation restructuring manufacturing site clarecastle ireland group enter annuity buyout agreement insurance company pay eur million plan asset settle define benefit obligation retire employee addition transfer value payment eur million plan asset deferred employee settle define benefit obligation group record settlement loss eur million transaction postemployment benefit opeb plan represent approximately group define benefit obligation consist postemployment healthcare life insurance scheme mainly plan mainly unfunde andor contributory employee group reimburse retire employee directly financial resource group major opeb plan close new member cost plan reimbursable medicare prescription drug improvement modernization act statutory funding requirement plan group funding plan extent tax efficient payment group plan usd million december ifrs funding status include reimbursement right fund opeb plan roche finance report roche group note roche group consolidate financial statement define benefit plan income statement millions chf post post pension employment total pension employment total plan benefit plan expense plan benefit plan expense current service cost past service income cost settlement gain loss total operating expense net interest cost define benefit plan total expense recognise income statement funding status fund group define benefit plan responsibility respective senior governing body board trustee sponsor employer manage base local statutory valuation follow legislation requirement respective jurisdiction plan establish qualified independent actuary carry statutory actuarial valuation regular basis actuarial assumption determine funding status statutory basis regularly assess local senior governing body funding status closely monitor corporate level unfunded plan mainly group german affiliate fully reserve pension obligation selffinance local affiliate operation ifrs funding status fund define benefit plan improve reimbursement right link postemployment medical plan represent expect reimbursement medical expenditure provide medicare prescription drug improvement modernization act define benefit plan fund status millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability report balance sheet define benefit plan asset define benefit plan liabilitie roche finance report note roche group consolidate financial statement roche group plan asset responsibility investment strategy fund plan respective senior governance body board trustee assetliability study perform regularly major pension plan study examine obligation post employment benefit plan evaluate investment strategy respect key financial measure expect return expect risk expect contribution expect funded status plan interdependent way goal assetliability study select appropriate asset allocation fund hold plan investment strategy develop optimise expect return manage risk contain fluctuation statutory fund status assetliability study include strategy match cash flow asset plan obligation group currently use longevity swap manage longevity risk plan asset manage internal external asset manager actual performance continually monitor pension fund governance body closely monitor corporate level financial statement difference interest income actual return plan asset remeasurement record directly comprehensive income actual return plan asset loss chf million gain chf million recognition plan asset limit present value economic benefit available refund plan reduction future contribution plan define benefit plan fair value plan asset reimbursement right millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january addition interest income plan asset remeasurement plan asset currency translation effect employer contribution employee contribution benefit pay fund plan benefit pay settlement administration cost december define benefit plan composition plan asset millions chf equity security debt security property cash money market instrument investment december asset invest variety different class order maintain balance risk return follow equity debt security mainly quote market price level fair value hierarchy property primarily private commercial property fund mainly observable input level fair value hierarchy cash money market instrument mainly invest financial institution credit rating low investment mainly consist alternative mortgage commodity insurance contract risk management purpose mainly observable input level fair value hierarchy unobservable input level fair value hierarchy include fair value plan asset group share nonvoting security fair value chf million chf million debt instrument issue group fair value chf million chf million roche finance report roche group note roche group consolidate financial statement define benefit obligation define benefit obligation calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth mortality rate present value define benefit obligation determine discount estimate future cash outflow interest rate highquality corporate bond government bond countrie deep market corporate bond corporate government bond denominate currency benefit pay maturity term approximate term relate pension obligation group final salarybase define benefit pension plan germany united kingdom close new participant active employee member pension plan time close new participant continue accrue benefit final salarybase define benefit pension plan new employee uk join group define contribution plan new employee germany join contributionbase plan minimum guarantee result proportion define benefit obligation relate closed plan expect decrease future define benefit pension plan switzerland final benefit contributionbase minimum guarantee remain open new employee define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january addition current service cost interest cost remeasurement demographic assumption financial assumption experience adjustment currency translation effect employee contribution benefit pay fund plan benefit pay unfunded plan benefit pay settlement past service income cost settlement gain loss december composition plan active member defer vested member retire member december plan geography switzerland united states germany rest world december duration year roche finance report note roche group consolidate financial statement roche group actuarial assumption actuarial assumption financial statement base requirement set ias employee benefit unbiased mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management base advice actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate salary benefit level inflation rate cost medical benefit actuarial assumption vary base local economic social condition actuarial assumption statutory valuation differ base local legal regulatory requirement demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity rate employee turnover disability early retirement base historical behaviour average life expectancy assume individual age follow define benefit plan average life expectancy age major scheme year male female country mortality table switzerland bvg projected cmi model united states rp project mp germany heubeck table g project cmi model rp table project mp datum heubeck table g mortality assumption pension plan switzerland base bvg apply continuous mortality investigation cmi model longterm rate longevity improvement december group mortality assumption pension plan germany heubeck table g apply cmi model longterm rate longevity improvement financial assumption base market expectation period obligation settle assumption actuarial valuation show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate determine reference interest rate highquality corporate bond government bond countrie deep market corporate bond expect rate salary increase base expected inflation rate adjustment reflect group late expectation longterm real salary increase expect rate pension increase generally link expected inflation rate funding status plan expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance medical cost trend rate account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development roche finance report roche group note roche group consolidate financial statement sensitivity analysis measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption follow table summarise impact change assumption present value define benefit obligation define benefit plan sensitivity define benefit obligation actuarial assumption millions chf increase decrease define benefit obligation life expectancy year increase discount rate increase decrease expect inflation rate increase decrease immediate medical cost trend rate increase decrease sensitivity analysis consider change assumption time leave assumption unchanged approach show isolated effect change individual assumption account assumption relate method carry sensitivity analysis prior year cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately chf million include estimate chf million additional contribution relate uk define benefit plan benefit pay unfunded plan estimate approximately chf million relate german define benefit plan roche finance report note roche group consolidate financial statement roche group equity compensation plan group operate equity compensation plan include separate plan chugai foundation medicine ifrs sharebase payment require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense equity compensation plan roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan roche connect roche option plan bonus stock award chugai foundation medicine plan total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf roche option plan exercise chugai foundation medicine plan exercise roche connect cost transaction equity total cash inflow outflow equitysettle equity compensation plan net transaction equity net cash outflow transaction equity mainly arise sale purchase equity instrument hold group potential conversion obligation arise group equity compensation plan note equity compensation plan roche stocksettle stock appreciation right group issue stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive non vote equity security reflect value appreciation market price nonvoting equity security grant date exercise date roche ssar plan million ssar available issuance tenyear period right nontradable equitysettle award sevenyear duration vest phase basis year roche finance report roche group note roche group consolidate financial statement roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total roche restrict stock unit plan group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance condition currently performance condition outstanding rsus december roche rsu plan million nonvoting equity security available issuance tenyear period roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december vest transferable roche performance share plan group offer future share nonvoting equity security awards discretion board director cash equivalent certain director key senior manager nontradable equitysettle award programme currently operate annual threeyear cycle roche performance share plan psp include value adjustment equivalent sum shareholder distribution group vest period attributable number share nonvoting equity security individual award grant share nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director award result zero share non vote equity security value adjustment depend achievement performance target roche finance report note roche group consolidate financial statement roche group roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million roche connect programme enable employee worldwide certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million cost plan chf million chf million roche option plan programme country ssar award plan employee right purchase nonvoting equity security exercise price specify grant date option nontradable equity settle award sevenyear duration vest phase basis year roche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable weighted average weighted average weight average number outstanding year remain exercise price number exercisable exercise price year grant thousands contractual life chf thousand chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year subject approval annual general meeting march issue march number award fair value award calculate grant date roche finance report roche group note roche group consolidate financial statement fair value measurement input measurement fair value grant date equity compensation plan follow fair value measurement roche roche roche stocksettle stock restrict performance roche appreciation right stock unit plan share plan option plan progressively cliff vest cliff vest progressively vest period year year year year contractual life year na na year number grant year thousand weight average fair value chf model binomial market pricea monte carlob binomial input option pricing model share price grant date chf exercise price chf expect volatility c na na expect dividend yield na na early exercise factor na na expect exit rate na na fair value roche rsus equivalent share price date grant b input parameter covariance matrix roche individual company peer group base threeyear history riskfree interest rate minus valuation take account define rank performance structure determine payout plan c volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour earning share nonvoting equity security basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number share nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf roche finance report note roche group consolidate financial statement roche group dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic division calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense financing cost financial income expense income taxis operate profit depreciation property plant equipment amortisation intangible asset impairment goodwill impairment intangible asset impairment reversal property plant equipment operating income expense define benefit plan operate expense equitysettle equity compensation plan net income expense provision bad debt reversal expense inventory writedown net gain loss disposal product adjustment cash generate operation roche finance report roche group note roche group consolidate financial statement cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity dividend pay millions chf dividend roche group shareholder dividend noncontrolle shareholder chugai dividend noncontrolle shareholder dividend withholding tax total liability arise financing activity movement carry value recognise asset liability millions chf cash flow noncash change foreign outflow financing business fair value exchange january inflow cost combination rate december debt interest payable derivative financial instrument net cash collateral receivables payable net total debt interest payable derivative financial instrument net cash collateral receivables payable net total significant noncash transaction significant noncash transaction roche finance report note roche group consolidate financial statement roche group risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral longterm forecasting controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset group consider financial asset default counterparty unlikely pay obligation group assess counterparty default group consider qualitative quantitative indicator eg overdue status base datum develop internally certain financial asset obtain external source major group receivables past day relate public customer risk default public customer consider low group reasonable supportable information demonstrate lag default criterion appropriate particular customer segment account receivable december group trade receivables chf billion chf billion subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective trade receivables management maximise collection unpaid amount group use allowance matrix estimate allowance doubtful account trade receivable expect credit loss ecl rate base group historical experience group expectation economic condition period receivables expect pay roche finance report roche group note roche group consolidate financial statement customer credit risk exposure base account receivable day overdue ifrs millions chf overdue overdue overdue credit total current month month year impair december gross carrying group expect credit loss rate allowance doubtful account age account receivable impaired ias millions chf december overdue impair overdue month overdue month overdue month overdue month overdue year total account receivable december group combine trade receivable balance national wholesale distributor mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion represent group consolidated trade receivables chf billion represent significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold trade receivables financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country trade receivable chf billion chf billion public private customer country group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action nature geographic location counterpartie account receivable overdue impair show table include balance national wholesalers southern europe public customer describe account receivable overdue net allowance doubtful account allowance nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland europe north america latin america japan asia australia oceania rest world total cash marketable security exclude equity security december group cash marketable security exclude equity security chf billion chf billion subject policy restricting exposure high quality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly roche finance report note roche group consolidate financial statement roche group cash cash equivalent hold bank financial institution predominantly rate investment grade respectively base moodys standard poor rating cash shortterm time deposit subject rule limit group exposure individual financial institution impairment cash cash equivalent measure month expect credit loss ecl basis reference external credit rating counterpartie reflect short maturity exposure group consider cash cash equivalent low credit risk base external credit rating investment marketable security exclude equity security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity counterpartie credit rating baa moodys bbb standard poor credit risk counterpartie external rating investment grade nonrate closely monitor review individual basis rating analysis cash marketable security exclude equity security market value millions chf ifrs ias fair value amortise oci cost month month available loan total ecl ecl total forsale receivables aaa range aa range range bbb range total investment grade bbb range investment grade unrated total gross carrying amount loss allowance loss allowance relate fair value oci affect carry marketable security exclude equity security book correspond oci reserve instead debt security amortise cost fair value oci investment grade consider low risk impairment allowance determine month expect credit loss ecl reference external credit rating counterpartie debt security group observe significant increase credit risk require application lifetime expect credit loss impairment model material impact result revise impairment approach ifrs addition material movement loss allowance master netting agreement group enter derivative transaction collateral agreement international swap derivative association isda master netting agreement respective counterpartie order mitigate counterparty risk agreement amount owe counterparty single day respect transaction outstanding currency aggregate single net payable party isda agreement meet criterion offset balance sheet group currently enforceable right offset recognise amount right offset enforceable occurrence future event default credit event contract term december significant financial asset term renegotiate impairment loss total impairment loss financial asset exclude equity investmentssecuritie ifrs amount chf million total impairment loss availableforsale asset ias amount chf million liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement december group unused committed credit line financial institution total chf billion chf billion chf billion serve backstop line commercial paper program roche finance report roche group note roche group consolidate financial statement remain undiscounted cash flow contractual maturity financial liability include estimate interest payment show table contractual maturity financial liability millions chf carry value total year year year year december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability takeorpay commitments group enter contract manufacturing agreement company develop manufacturing capacity flexibility mainly pharmaceutical division future minimum takeorpay commitment agreement total potential commitment group chf billion december chf billion market risk market risk arise change market price mainly foreign exchange rate interest rate group financial asset financial liability affect group financial result equity valueatrisk group use valueatrisk var measure impact market risk financial instrument var indicate value range give financial instrument fluctuate preset probability result movement market price var calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate actual future gain loss associate treasury activity differ materially var analysis inherent limitation associate predict timing change interest rate foreign exchange rate equity investment price particularly period high market volatility furthermore var include effect change credit spread market risk financial instrument millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component remain largely stable foreign exchange component decrease favourable exposure mix price component arise mainly movement equity security price decrease low volatility hold asset roche finance report note roche group consolidate financial statement roche group foreign exchange risk group use swiss franc report currency result expose movement foreign currency mainly dollar japanese yen euro group foreign exchange risk management strategy preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously immunise unfavourable development foreign exchange rate interest rate risk group mainly raise debt fix rate basis bond note group expose movement interest rate mainly dollar swiss franc euro float rate financial instrument shortterm debt group interest rate risk management strategy optimise net interest result group use forward contract option interest rate swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment capital management group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event capitalisation report senior management group regular internal management reporting show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group net equity significantly impact genentech transaction note group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine chugai management roche finance report roche group note roche group consolidate financial statement financial instrument accounting classification fair value fair value financial asset liability carry value show consolidated balance sheet follow carry value fair value financial instrument ifrs millions chf financial instrument mandatorily financial financial fair value instrument fair value asset total profit fair value hedging amortise financial carrying loss oci instrument cost liability value fair value december ifrs noncurrent asset equity investment financial noncurrent asset account receivable marketable security equity security debt security money market instrument time account month cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability carry value fair value financial instrument ia millions chf fair value total available hedge fair value loan financial carry forsale instrument designate receivables liability value fair value december ia noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability roche finance report note roche group consolidate financial statement roche group fair value bond note level calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period fair value hierarchy table analyse financial instrument carry fair value valuation method different level define follow level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial instrument millions chf level level level total december ifrs marketable security equity security fair value profit loss debt security fair value oci money market instrument fair value oci derivative financial instrument equity investment fair value oci equity investment fair value profit loss financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value december ia marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value fair value hierarchy adjust reflect presentational change require result implement ifrs financial instrument describe note level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument group determine level fair value follow valuation technique marketable security derivative financial instrument base valuation model use observable market datum interest rate yield curve foreign exchange rate imply volatility similar instrument measurement date equity investment fair value oci fair value profit loss previously availableforsale investment base valuation model use recently publish observable market datum group recognise transfer level fair value hierarchy end report period transfer occur significant transfer level level vice versa year time account month account amortise cost ifrs result long include fair value hierarchy analysis account availableforsale ia include fair value hierarchy roche finance report roche group note roche group consolidate financial statement level fair value detail determination level fair value measurement set contingent consideration arrangement millions chf january arise business combination utilise settlement total unrealised gain loss include income statement unused amount reverse record general administration additional create record general administration discount unwind include financing cost total gain loss include comprehensive income currency translation effect december contingent consideration provision decrease mainly reversal provision payment milestone chf million income net mainly reversal remain provision relate trophos acquisition payment chf million milestone relate dutalys acquisition contingent consideration arrangement group party certain contingent consideration arrangement arise business combination fair value determine consider expect payment discount present value riskadjusted average discount rate expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario significant unobservable input forecast sale performance criterion riskadjuste discount rate estimate fair value increase forecast sale performance criterion rate higher riskadjuste discount rate low december total potential payment contingent consideration arrangement chf billion chf billion follow potential payment contingent consideration arrangement millions chf acquisition year acquire operating segment dutalys roche pharmaceutical santaris roche pharmaceutical trophos roche pharmaceutical geneweave diagnostic genia diagnostic ariosa diagnostic diagnostic december roche finance report note roche group consolidate financial statement roche group derivative financial instrument group enter currency swap certain nonus dollar debt instrument cash collateral agreement enter counterpartie currency swap mitigate counterparty risk follow table set carry value derivative financial instrument amount subject master netting agreement derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative carry value derivative financial instrument derivative subject master netting agreement collateral arrangement net collateral arrangement november group complete tender offer repurchase eur million fix rate note march result hedge terminate cash receive group counterparty movement cash collateral receivable accrue liability millions chf january net cash deliver group fair value currency translation effect december hedge account transition ifrs note group elect restate comparative information result certain information require ifrs provide describe group risk management strategy hedge transaction exposure arise foreign currency flow monetary position hold foreign currency generate appropriate mix fix float rate exposure level hedging depend market condition business requirement group group designate annually specific interest rate risk management objective ensure predetermine range interest rate risk exposure float rate hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessment report date ensure economic relationship exist hedge item hedging instrument group perform qualitative assessment hedge effectiveness critical term match method critical term hedge item hedge instrument match group conclude risk hedge hedged item hedge instrument sufficiently align inherent mismatch hedge relationship hedge ratio apply actual quantity hedge hedge accounting roche finance report roche group note roche group consolidate financial statement accounting treatment source ineffectiveness prospective effectiveness assessment method risk category prospective effectiveness accounting treatment potential source ineffectiveness assessment method interest rate foreign exchange rate fluctuation cash flow hedge counterparty credit risk critical term match foreign exchange rate fluctuation cash flow hedge low volume hedge item critical term match counterparty credit risk interest rate fluctuation fair value hedge counterparty credit risk critical term match ineffective portion hedge accounting recognise income statement include financial income expense measure hypothetical derivative method cash flow hedge cumulative dollar offset method fair value hedge december potential source ineffectiveness individually collectively result material amount actual ineffectiveness report hedge accounting relationship table show fair value nominal amount derivative financial instrument include range time nominal hedge instrument designate hedge instrument cash flow hedge fair value hedge december group follow cash flow hedge fair value hedge designate qualifying hedge relationship fair value nominal amount derivative hedge accounting december fair value asset fair value liability nominal million chf million chf maturity range cash flow hedge risk hedge interest rate foreign exchange rate fluctuation crosscurrency swap eur million fix usd risk hedge foreign exchange rate fluctuation forward exchange contract jpy billion total fair value hedge risk hedge interest rate fluctuation interest rate swap usd million interest rate swap eur million interest rate swap chf million total fair value derivative financial instrument hedge accounting include current asset note current liability note group approach manage market risk include interest rate risk foreign currency risk discuss market risk section note cash flow hedge group enter crosscurrency swap hedge foreign exchange interest rate risk bond note issue group denominate euro december instrument record net fair value liability chf million chf million ineffective portion chugai enter forward exchange contract hedge foreign translation exposure swiss franc dollar december instrument record fair value asset chf million fair value liability chf million fair value asset chf million ineffective portion carry item designate hedge item cash flow hedging relationship million chf asset liability bond note risk hedge crosscurrency swap interest rate foreign exchange rate fluctuation bond note inventory risk hedge forward exchange contract foreign exchange rate fluctuation inventory roche finance report note roche group consolidate financial statement roche group hedging reserve continue hedge relationship millions chf cross forward currency exchange total swap contract january gain loss take equity transfer income statement income taxis noncontrolle interest currency translation effect december entire transfer income statement report financial income expense hedging relationship hedge accounting long apply change hedge reserve equity show note expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total year year total year year cash inflow cash outflow total cash inflow outflow undiscounte cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity expect cash flow qualify cash flow hedge impact profit loss million chf total year year total year year cash inflow cash outflow total cash inflow outflow fair value hedge group enter interest rate swap hedge exposure change fair value fixedterm debt instrument respect benchmark interest rate december instrument record fair value liability chf million chf million fair value asset chf million chf million fair value adjustment chf million record interest rate swap chf million fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument group approach manage market risk include interest rate risk discuss market risk section note carry item designate hedge item fair value hedge relationship million chf fair value fair value adjustment adjustment liability cumulative current year bond note risk hedged interest rate swap interest rate fluctuation bond note net investment hedge group net investment hedge roche finance report roche group note roche group consolidate financial statement relate party control shareholder share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own share represent issue share group consist ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri dr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool mr andr hoffmann dr andreas oeri members board director roche holding ltd mr hoffmann receive remuneration totalling chf chf dr oeri receive remuneration totalling chf chf transaction group individual member shareholder group exception dr jrg duschmal work postdoc roche end september subsidiary associate list group subsidiary associate include note list exclude chugais subsidiary material company notably company inactive dormant liquidation transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associate key management personnel total remuneration key management personnel chf million chf million member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee dr franz members corporate executive committee cec roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member cec members cec participate certain equity compensation plan describe term vest condition fair value award disclose note new member cec include table calendar year join cec similarly member cec retire partway year include calendar year leave cec remuneration member board director corporate executive committee millions chf salary include cashsettle bonus bonus stock award social security cost pension postemployment benefit equity compensation plan board fee employee benefit total purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition roche finance report note roche group consolidate financial statement roche group detailed disclosure executive remuneration require swiss law include remuneration report include annual report page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration member board director corporate executive committee ifrs basis table deduct bonus stock award ifrs basis equity compensation plan ifrs basis add bonus stock award swiss legal basis equity compensation plan swiss legal basis total remuneration member board director corporate executive committee swiss legal basis include social security cost board director annual report corporate executive committee annual report bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year subject approval annual general meeting march issue march number award fair value award calculate grant date equity compensation plan member corporate executive committee receive equity compensation show follow table number right option award grant member corporate executive committee roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan contribution pay member corporate executive committee millions chf roche connect transaction member board director corporate executive committee pension totalling chf million pay group corporate executive committee member chf million define benefit plan transaction group define benefit plan employee group describe note roche finance report roche group note roche group consolidated financial statement list subsidiary associate follow list group subsidiary associate excludes chugais subsidiary material company notably company inactive dormant liquidation list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich stock code share ro valor stock code genussschein rog valor isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million united states senseonics holdings inc germantown usd stock exchange new york stock exchange nysemkt stock code sen isin usu market capitalisation usd million nonliste company share capital equity interest country company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ar roche diabetes care argentina sa tigre ar australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited north ryde aud roche product pty limited dee aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostic gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche product limit minsk usd belgium nv roche sa brussels eur roche diagnostic belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche product limit hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd sapac corporation ltd hamilton cad syntex pharmaceuticals international limited hamilton usd bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico e farmacuticos sa paulo brl roche diabetes care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp roche finance report note roche group consolidate financial statement roche group share capital equity interest country company city millions china roche china holding ltd shanghai usd roche shanghai pharmaceuticals consulting co ltd shanghai cny roche shanghai pharmaceuticals trading co ltd shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai ltd shanghai usd roche diagnostic suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche sa bogot cop costa rica roche services america sociedad de responsabilidad limitada san jose crc roche servicios sa heredia usd cte divoire roche cte divoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche medicinalvarer og kemikalier hvidovre dkk roche diagnostic hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic producto roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp rodiagnostic egypt trading sae giza egp el salvador productos roche el salvador sa de cv antiguo cuscatlan svc estonia roche eesti tallinn eur finland roche diagnostic oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostic france sas meylan eur roche sas boulognebillancourt eur trophos sa marseille eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlung gmbh grenzachwyhlen eur fmi germany gmbh penzberg eur galenus mannheim pharma gmbh mannheim eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen eur roche diabete care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche privacy gmbh grenzachwyhlen eur roche pvt gmbh waiblingen eur roche real estate service mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur signature diagnostic gmbh potsdam eur ghana roche product ghana limit accra ghs greece roche hellas sa athens eur roche diagnostic hellas sa athens eur guatemala producto roche guatemala sociedad annima guatemala gtq honduras producto roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diabetes care india private limited mumbai inr roche diagnostic india private limited mumbai inr roche product india private limited mumbai inr viewics india private limited pune inr indonesia pt roche indonesia jakarta idr iran roche par co ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd hod hasharon il roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions italy roche diabetes care italy spa monza eur roche diagnostic spa monza eur roche spa monza eur japan roche dc japan k k tokyo jpy roche diagnostic kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur macedonia roche makedonija dooel skopje eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd petale jaya myr roche services asia pacific sdn bhd kuala lumpur myr mauritius roche products mauritius ltd quatre borne mur mexico producto roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherland roche diabete care nederland bv almere eur roche diagnostic nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholde bv woerden eur new zealand roche diagnostic nz limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche product limited lagos ngn norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panama sa panama city pab producto roche interamericana sa prisa panama city usd peru producto roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippine roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostic polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diabetes care rus moscow rub limited liability company roche diagnostic rus moscow rub roche moscow ltd moscow rub saudi arabia roche product saudi arabia llc jeddah sar serbia roche doo beograd belgrade eur singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur roche finance report note roche group consolidate financial statement roche group share capital equity interest country company city millions south africa kapa biosystem pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche diagnostic proprietary limited midrand zar roche product proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain roche diabetes care spain sl sant cugat del valls eur roche diagnostic sl sant cugat del valls eur roche farma sa madrid eur sweden roche ab solna sek roche diagnostic scandinavia ab solna sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmann la roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabete care switzerland ltd rotkreuz chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey infogenetik molekler bilgi hizmetleri anonim sirketi istanbul try roche diagnostic turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirate roche diabetes care middle east fzco dubai ae roche diagnostic middle east fzco dubai ae roche pharmaceutical middle east fzco dubai ae united kingdom intermune holding limit welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostic limited burgess hill gbp roche hold uk limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp tusk therapeutics limit welwyn garden city gbp roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions united states adheron therapeutics inc south san francisco usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc belmont usd bioveris corporation indianapoli usd flatiron health inc new york usd forsight vision inc south san francisco usd foundation medicine security corporation cambridge usd foundation medicine inc cambridge usd genentech usa inc south san francisco usd genentech inc south san francisco usd geneweave biosciences inc los gatos usd hoffmannla roche inc little fall usd survive corp south san francisco usd igen international inc pleasanton usd igen ls llc pleasanton usd ignyta inc san diego usd intermune inc south san francisco usd iquum inc marlborough usd jecure therapeutics inc san diego usd kapa biosystem inc wilmington usd memory pharmaceutical corp little falls usd mysugr inc encinitas usd roche diabetes care inc indianapoli usd roche diagnostic corporation indianapoli usd roche diagnostic hematology inc westborough usd roche diagnostic operation inc indianapoli usd roche health solutions inc indianapoli usd roche holdings inc south san francisco usd roche laboratory inc little fall usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequence solutions inc pleasanton usd roche tcrc inc new york usd seragon pharmaceuticals inc south san francisco usd spring bioscience corp pleasanton usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc san jose usd uruguay roche international ltd montevideo branch montevideo uyu venezuela producto roche sa caracas vef vietnam roche vietnam company limit ho chi minh city usd share capital local currency unit roche finance report note roche group consolidate financial statement roche group significant accounting policy consolidation policy subsidiary company group control group control entity group expose right variable return involvement entity ability affect return power entity company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control associate company group exercise power exercise significant influence control account equity method segment report purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation annual financial statement present swiss franc group company use local currency functional currency certain group company use currency dollar swiss franc euro functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc translate swiss franc yearend rate exchange income statement statement cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive income revenue sale revenue sale good supply product sale service render recode sale sale recognise promise customer contract performance obligation satisfied transferring control promise good service customer control promise good service refer ability direct use obtain substantially remain benefit good service control usually transfer shipment delivery receipt good customer service render accordance delivery acceptance term agree customer good subject installation instrument sell diagnostic division sale generally recognise completion installation customer site customer acceptance sale recognise transaction price base consideration group expect receive exchange good service exclude amount collect behalf party value add taxis taxis directly link sale contract contain performance obligation transaction price allocate performance obligation base relative standalone selling price roche finance report roche group note roche group consolidate financial statement instrument diagnostic division sell good reagent consumable service single contract contract combine revenue recognition purpose sale recognise satisfaction performance obligation contract instrument sell cash instalment sale transaction available customer finance lease operating lease transaction finance lease arrangement group transfer substantially risk reward ownership customer treat finance lease arrangement sale finance lease recognise amount represent fair value instrument approximate present value minimum lease payment arrangement interest rate embed finance lease arrangement approximately market rate sale finance lease comparable revenue outright sale finance income finance lease arrangement long month defer subsequently recognise base pattern approximate use effective interest rate method record royalty operating income operating lease sale operating lease recognise straightline basis lease term lease revenue entirely variable subject subsequent reagent sale performance obligation deliver reagent satisfied sale net discount base estimate relate obligation include standalone selling price fair value require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise contract distributor sale recognise good physically transfer distributor consignment arrangement distributor act agent case sale recognise control good transfer endcustomer distributor commission present marketing distribution commission similar payment distributor act principal deduct sale payment exchange distinct service consideration receive group exchange good service fix variable variable consideration recognise consider highly probable significant revenue reversal occur underlie uncertainty relate variable consideration subsequently resolve common element variable consideration pharmaceutical division list government regulatory mandatory price reduction consist mandatory price reduction major element b drug discount program medicaid plan contractual price reduction include rebate chargeback result contractual agreement primarily volumebase performancebase cash discount include credit offer wholesaler remit payment purchase contractually define incentive period customer return reserve allowance establish expect product return revenue product sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount earn claim related sale estimate consideration historical experience current contractual statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust effect sale earning period adjustment sale reduction expect withhold customer settlement contractual price reduction cash discount record balance sheet deduction trade receivables sale reduction separately payable customer governmental health authority healthcare regulatory authority record balance sheet accrue liability provision sale return record balance sheet provision group recognise defer income contract liability consideration receive receivable group transfer promise good service customer defer income mainly relate remain performance obligation good free charge certain patient access similar programme reagent consumable service remain performance obligation partially unsatisfie longterm contract include defer income relate amount group expect receive good service transfer customer exist non cancellable enforceable contract mainly associate contract minimum purchase commitment related reagent consumable previously sell instrument monitor maintenance service contract original duration year group elect practical expedient disclose transaction price remain performance obligation end report period point time group expect recognise sale roche finance report note roche group consolidate financial statement roche group royalty operating income royalty operating income include royalty income income outlicense agreement income disposal product item royalty income earn licence recognise underlie sale record licensee income outlicense agreement typically arise receipt upfront milestone similar payment party grant licence product technologyrelate intellectual property ip outlicense agreement entered obligation include commitment conduct research latestage development regulatory approval comarkete manufacturing licence grant usually right use ip generally unique basis allocate revenue performance obligation make use residual approach upfront payment licensing fee usually recognise grant licence income shall defer performance obligation residual approach defer income release recognise revenue performance obligation satisfy milestone payment typically receive reach specific scientific milestone development milestone achieve certain annual sale milestone commercial milestone development milestone income recognise point time highly probable respective milestone event criterion achieve risk revenue reversal consider remote commercial milestone income accrue recognise revenue highly probable annual sale milestone reach period payment receive disposal product similar right recognise revenue transfer control right extent payment relate performance obligation portion defer residual approach recognise revenue activity manufacturing service render income profitshare arrangement collaboration partner recognise underlie sale cost sale record collaboration partner include income service render usually group primary business activity extent revenue record sale recognise control transfer performance obligation satisfy cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research development activity expense incur follow internal research cost incur purpose gain new scientific technical knowledge understand internal development cost incur application research finding knowledge plan develop new product commercial production development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation intangible asset meet prior obtain marketing approval regulatory authority major market postmarkete study regulatory approval phase iv cost pharmaceutical business generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure acquire inprocess research development resource obtain inlicense arrangement business combination separate asset purchase capitalise intangible asset acquire asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy subsequent internal research development cost incur post acquisition treat way internal research development cost research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset roche finance report roche group note roche group consolidate financial statement employee benefit shortterm employee benefit include wage salary social security contribution pay annual leave sick leave profit share bonus nonmonetary benefit current employee cost recognise operating result employee render associate service group recognise liability profit share bonus contractually oblige past practice create constructive obligation longterm employee benefit include longservice sabbatical leave longservice benefit longterm disability benefit expect cost benefit accrue period employment change carry value longterm employee benefit liability recognise operating result termination benefit payable employment terminate group normal retirement date employee accept voluntary redundancy exchange benefit termination cost recognise early group long withdraw offer benefit group recognise related restructuring cost pension postemployment benefit define contribution plan group contribution recognise operating result employee render associated service prepay contribution recognise asset extent cash refund reduction future payment available define benefit plan liability recognise balance sheet present value define benefit obligation fair value plan asset change net define benefit liability recognise occur follows recognise income statement current service cost charge appropriate income statement head operating result past service cost include curtailment gain loss recognise immediately general administration operating result settlement gain loss recognise general administration operating result net interest net define benefit liability recognise financing cost recognise comprehensive income actuarial gain loss arise experience adjustment difference previous assumption actually occur change actuarial assumption return plan asset exclude amount include net interest net define benefit liability change limit recognition plan asset exclude amount include net interest net define benefit liability net interest net define benefit liability comprise interest income plan asset interest cost define benefit obligation interest effect limit recognition pension asset net interest calculate discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan equity compensation plan fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity roche finance report note roche group consolidate financial statement roche group property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee finance lease exist substantially risk reward ownership transfer group finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt finance lease asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method operating lease exist substantially risk reward ownership transfer group payment operating lease charge income straightline basis period lease group lessor certain asset mainly diagnostic instrument lease party customer finance operating lease arrangement transaction enter separate contract combine contract include reagent consumable service finance lease finance lease asset report receivables equal net investment lease sale finance lease recognise amount represent fair value instrument approximate present value minimum lease payment arrangement finance income finance lease arrangement long month defer subsequently recognise base pattern approximate use effective interest method record royalty operating income operating lease sale operating lease recognise straightline basis lease term lease revenue entirely variable subject subsequent reagent sale performance obligation reagent satisfied sale net discount base estimate relate obligation include standalone selling price fair value require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise merger acquisition business combination business combination account acquisition method accounting date acquisition group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest acquire business consideration transfer measure fair value date acquisition group acquire ownership acquire business noncontrolle interest record fair value proportion fair value acquire net asset attributable noncontrolle interest directly attributable acquisitionrelated cost expense incur general administration expense roche finance report roche group note roche group consolidate financial statement asset acquisition asset acquisition acquisition legal entity qualify business combination date acquisition group initially recognise individual identifiable asset acquire liability assume cost represent cash consideration pay date acquisition allocate individual identifiable asset liability date acquisition subsequent consideration performancerelate development milestone recognise intangible asset specific milestone achieve transaction rise goodwill directly attributable acquisitionrelated cost expense incur general administration expense goodwill goodwill arise business combination excess consideration transfer acquire business underlie fair value net identify asset acquire goodwill amortise test impairment annually occurrence indication impairment intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination initially record fair value available use intangible asset amortise straight line basis useful life intangible asset review impairment reporting date estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost disposal value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate long term interest rate impairment loss arise useful life asset review necessary future depreciation amortisation charge accelerate impairment loss subsequently decrease decrease relate objectively event occurring impairment recognise previously recognise impairment loss reverse income statement impairment reversal impairment goodwill goodwill assess impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit recoverable cashgenerate unit high fair value cost disposal value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss acquire business include cash generating unit permanently cease operate treat disposal business separately identifiable goodwill generate initial acquisition business factor goodwill entirely unrelated continue operation cashgenerating unit goodwill deem dispose fully impair impairment testing methodology describe note inventory inventory state low cost net realisable value cost finish good work process intermediate include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense roche finance report note roche group consolidate financial statement roche group receivables include account receivable policy applicable january receivables carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance receivable represent right consideration unconditional exclude contract asset allowance doubtful account record expect credit loss term receivables estimate base specific indicator age customer balance specific credit circumstance group historical loss rate category customer adjust forwardlooke macroeconomic datum expense doubtful trade receivables recognise marketing distribution expense trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience receivable write partly reasonable expectation recovery receivable write group continue engage enforcement activity attempt recover receivable recovery recognise profit loss trade lease receivables group apply simplified approach prescribe ifrs requirespermit use lifetime expect loss provision initial recognition receivables group measure allowance doubtful account equal credit loss expect lifetime trade lease receivables policy applicable january receivables carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record objective evidence group able collect amount estimate base specific indicator age customer balance specific credit circumstance group historical experience take account economic condition expense doubtful trade receivables recognise marketing distribution expense trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash equivalent readily convertible know amount cash subject insignificant risk change fair value maturity month date acquisition provision contingency provision recognise legal constructive obligation incur probably lead outflow resource reliably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise discount time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available financial instrument policy applicable january january group classify financial instrument follow measurement category disclose note amortise cost fair value oci fair value oci equity investment fair value profit loss include hedging instrument roche finance report roche group note roche group consolidate financial statement classification depend group business model manage financial asset contractual term cash flow group reclassifie debt security financial asset amortise cost business model manage asset change initial recognition group measure financial asset fair value plus case financial asset fair value profit loss transaction cost directly attributable acquisition financial asset transaction cost financial asset carry fair value profit loss expense profit loss amortise cost asset hold collection contractual cash flow cash flow represent solely payment principal interest measure amortise cost provision impairment gain loss debt security subsequently measure amortise cost hedge relationship recognise profit loss asset derecognise impair interest income financial asset include financial income effective interest rate method asset amortise cost mainly comprise account receivable cash cash equivalent time account month fair value comprehensive income fair value oci financial asset hold collection contractual cash flow sell financial asset asset cash flow represent solely payment principal interest initially record subsequently carry fair value change fair value record comprehensive income recognition impairment gain loss interest revenue foreign exchange gain loss recognise profit loss financial asset derecognise cumulative gain loss previously recognise oci reclassify equity profit loss interest income financial asset include financial income effective interest rate method fair value comprehensive income asset mainly comprise money market instrument debt security equity investment fair value comprehensive income fair value oci equity investment private biotechnology company keep group strategic alliance effort asset subsequently measure fair value dividend recognise financial income profit loss dividend clearly represent recovery cost investment net gain loss recognise oci include fair value reserve asset derecognise cumulative gain loss previously recognise oci reclassify equity fair value reserve retain earning profit loss fair value profit loss financial asset performance evaluate fair value basis gain loss financial asset subsequently measure fair value profit loss hedge relationship recognise profit loss present financial income expense period arise fair value profit loss asset mainly comprise equity investmentssecuritie contingent consideration liability initially record subsequently carry fair value change fair value record general administration operating result income statement fair value profit loss hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense policy applicable january financial instrument classify follow category disclose note availableforsale fair value hedge instrument fair value designate loan receivables availableforsale nonderivative financial asset designate classified financial asset category availableforsale asset initially record subsequently carry fair value change fair value record comprehensive income impairment interest foreign exchange component investment derecognise cumulative gain loss equity reclassify financial income expense availableforsale asset mainly comprise marketable security fair value hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense roche finance report note roche group consolidate financial statement roche group fair value designate nonderivative financial instrument designate fair value profit loss initial recognition designate fair value instrument initially record subsequently carry fair value change fair value record income statement designate fair value instrument mainly comprise contingent consideration liability change fair value record general administration operating result loan receivables nonderivative financial asset fix determinable payment quote active market loan receivables initially record fair value subsequently carry amortise cost effective interest rate method impairment loss loan receivables mainly comprise account receivable cash cash equivalent change policy january follow item financial liability nonderivative financial liability financial liability initially record fair value transaction cost subsequently carry amortise cost effective interest rate method financial liability mainly comprise debt trade payable debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer financial liability derecognise contractual obligation discharge cancel expire impairment financial asset policy applicable january group recognise loss allowance expect credit loss ecl financial asset measure amortise cost debt security measure fair value oci trade lease receivables group measure allowance doubtful account equal lifetime ecl debt security carry fair value oci debt security financial asset amortise cost determine low credit risk base external credit rating counterpartie group measure loss allowance equal month ecl group consider debt security low credit risk credit risk rating equivalent globally understand definition investment grade group consider baa moodys bbb standard poor credit risk debt security carry fair value oci debt security financial asset amortise cost increase significantly initial recognition group measure loss allowance equal lifetime ecl group assume credit risk instrument increase significantly day past financial asset write partially realistic prospect recovery generally case group determine customer asset source income generate sufficient cash flow repay amount subject writeoff financial asset write subject enforcement activity order comply group policy recovery amount policy applicable january financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale equity security market value original cost market value original cost sustain sixmonth period consider impaired financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry comprehensive income difference original cost fair value roche finance report roche group note roche group consolidated financial statement impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly comprehensive income hedge accounting group use derivative manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forwards contract option group generally limit use hedge account certain significant transaction qualify hedge accounting hedging relationship meet strict condition eligibility hedge hedge instrument formal designation documentation hedge effectiveness reliability measurement transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income expense cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge instrument record fair value effective portion hedge include comprehensive income ineffective portion report financial income expense hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial item cumulative change fair value hedge instrument record comprehensive income include initial carrying value nonfinancial item date recognition cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income expense forecast transaction affect net income fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future tax liability uncertain accrual record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience defer tax asset liability recognise temporary difference tax basis asset liability carry value defer tax asset recognise extent probable future taxable profit available unused tax loss utilise current defer tax asset liability offset income taxis levy taxation authority legally enforceable right offset defer taxis determine base currently enact tax rate applicable tax jurisdiction group operate equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument hold group potential conversion obligation arise group equity compensation plan roche finance report note roche group consolidate financial statement roche group change accounting policy group implement follow new standard include consequential amendment standard date initial application january ifrs financial instrument ifrs revenue contract customer definition business amendment ifrs group implement minor amendment exist standard interpretation material impact group overall result financial position new standard revise standard amend standard interpretation material impact group overall result financial position nature effect change relevant group financial statement give ifrs financial instrument effective january group implement ifrs financial instrument new standard replace ias financial instrument recognition measurement standard deal classification recognition measurement include impairment financial instrument introduce new hedge accounting model new standard result increase volume disclosure information annual financial statement classification measurement financial instrument previously marketable security classify availableforsale ia new standard equity security classify fair value profit loss debt security money market instrument fair value comprehensive income oci time account month amortise cost group elect classify certain strategic equity investment fair value oci strategic equity investment sell cumulative include fair value reserve transfer retain earning impairment financial asset january group change methodology assess impairment financial asset incur loss model ias expect credit loss model ifrs accordance transitional provision ifrs group restate prior period reassess impairment allowance new approach january hedge account new standard introduce new hedge accounting model require hedge accounting relationship base group risk management strategy objective discontinue relationship long qualify hedge accounting group apply revise hedge accounting guidance hedge relationship prospectively effect january hedge accounting relationship designate previous ias guidance continue valid hedge accounting relationship accordance ifrs transition approach group apply exemption retrospective application classification measurement requirement include impairment mean comparative result restate difference carry amount financial asset reclassification adjustment adoption ifrs recognise retain earning reserve january accordingly information present generally reflect requirement ifrs ias presentational change result implement ifrs group number presentational change statement comprehensive income statement change equity note roche finance report roche group note roche group consolidated financial statement impact initial application ifrs impact initial application ifrs group consolidate balance sheet group consolidated equity follow revise roche group consolidate balance sheet select item millions chf balance balance application january january ifrs revised account receivable defer tax asset total net asset capital reserve attributable roche shareholder total equity revise roche group consolidated equity select item millions chf application balance balance ifrs january january net tax revise retain earning fair value reserve total equity reclassification equity chf million net tax transfer fair value reserve retain earning january relate unrealised gain equity instrumentsinvestment reclassification fair value profit loss previously classify availableforsale addition decrease chf million net tax retain earning additional bad debt allowance trade lease receivables result apply expect credit loss model ifrs follow table reconcile carry amount financial asset ias carry amount ifrs transition ifrs january reclassification financial liability reclassification financial instrument adoption ifrs millions chf remeasurement balance balance application january measurement category january ifrs revise original new ias ifrs current financial asset account receivable loan receivables amortise cost equity security availableforsale fair value profit loss debt security availableforsale fair value oci money market instrument availableforsale fair value oci time account month availableforsale amortise cost derivative financial instrument fair value profit fair value profit loss loss financial current asset loan receivables amortise cost noncurrent financial asset equity investment fair value availableforsale fair value oci oci equity investment fair value availableforsale fair value profit profit loss loss financial noncurrent asset loan receivables amortise cost roche finance report note roche group consolidate financial statement roche group ifrs revenue contract customer effective january group implement ifrs revenue contract customer new standard replace ias revenue ias construction contract ifrs establishe comprehensive framework determine revenue recognise contain new requirement relate presentation core principle framework revenue recognise dependent transfer promise good service customer reflect consideration receive exchange good service objective standard provide fivestep approach revenue recognition include identify contract customer identify performance obligation determine transaction price allocate transaction price performance obligation recognise revenue performance obligation satisfied judgement need apply include make estimate assumption multipleelement contract identify performance obligation constrain estimate variable consideration allocate transaction price performance obligation lease component particularly diagnostic business outlicense agreement new standard result increase volume disclosure information annual financial statement change introduce standard relevant roche group new standard provide additional requirement guidance relevant group notably follow area revenue licence intellectual property include salesbased royalty constrain estimate variable consideration eg development milestone provide material right receive additional good free charge certain patient access programme regard separate performance obligation material impact change new standard clarify allocate sale include treatment discount element multipleelement contract recognise sale element contract enter diagnostic division typically include obligation instrument include provide leasing arrangement reagent consumable service require use estimate assumption judgement apply guidance practice material impact guidance outlicense agreement pharmaceutical division enter obligation include commitment conduct research latestage development regulatory approval comarketing manufacturing settle combination upfront payment milestone payment license fee reimbursement service provide consider commitment single performance obligation separate one scope ifrs straightforward require judgement depend conclusion result revenue calculate inception recognise spread term long performance obligation answer new standard different currently new standard provide exemption salesbase royalty licence intellectual property continue recognise revenue underlie sale incur transition approach use practical expedient group apply retrospective method transition certain practical expedient permit standard transition notably relief restate contract begin complete complete january relief provide disclosure requirement ifrs paragraph comparative period transaction price allocate remain performance obligation new standard include use practical expedient modify timing amount revenue recognise restatement necessary presentational change result implement ifrs group presentational change income statement include subtotal revenue create new note revenue note definition business amendment ifrs october international accounting standard board issue amendment ifrs business combination amendment clarify definition business add optional concentration test aid assessment transaction represent business combination simply substance purchase single asset group similar asset amendment mandatory early adopt amendment particularly relevant acquisition carry group value acquire company largely consist right single product technology effective january group early implement amendment prospective application restatement comparative period information roche finance report roche group note roche group consolidated financial statement note expand rename merger acquisition include transaction account business combination asset acquisition asset acquisition acquisition legal entity qualify business combination ifrs cash consideration pay asset acquisition transaction date subsequent additional contingent payment achievement performancerelate development milestone present line asset acquisition disclose note subsequent consideration performancerelate development milestone transaction treat asset acquisition recognise intangible asset specific milestone achieve previously intangible asset acquire asset acquisition include line item purchase intangible asset statement cash flow addition note intangible asset future new revise standard group currently assess potential impact new revise standard interpretation mandatory january group apply base analysis date group anticipate material impact group overall result financial position effect implementation ifrs lease summarise ifrs lease group implement new standard effective january ifrs replace exist lease guidance include ias lease set principle recognition measurement lease new standard result increase volume disclosure information annual financial statement main effect group ifrs introduce single onbalance sheet lease accounting model lessee require lessee recognise asset liability lease include operating lease group assess potential impact expect carry value lease asset increase approximately chf billion lease liability expect increase similar date implementation application new standard result currently report operating lease cost record interest expense give lease involve current low interest rate environment group currently expect effect material group currently finalise exact impact new standard transition approach use practical expedient group apply cumulative catchup method transition cumulative effect adopt ifrs recognise adjustment opening balance retain earning january restatement comparative information practical expedient permit standard notably reassess transition existing contract contain lease recognition exemption shortterm lease lease lowvalue asset presentational change result implement ifrs group number presentational change notably present rightofuse asset separate line item balance sheet include lease liability current non current liability new note lease create include increase volume require disclosure information roche finance report report roche management internal control financial reporting roche holding ltd basel report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg ag audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set page christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group statutory auditor report statutory auditor report general meeting roche holding ltd basel report audit consolidated financial statement opinion audit consolidated financial statement roche holding ltd subsidiary group comprise consolidated balance sheet december consolidated income statement consolidate statement comprehensive income consolidate statement change equity consolidate statement cash flow year end note consolidate financial statement include summary significant accounting policy opinion consolidated financial statement page true fair view consolidate financial position group december consolidated financial performance consolidated cash flow year end accordance international financial reporting standard ifrs comply swiss law basis opinion conduct audit accordance swiss law international standard auditing isa swiss auditing standard responsibility provision standard describe auditor responsibility audit consolidated financial statement section report independent group accordance provision swiss law requirement swiss audit profession iesba code ethic professional accountant fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion key audit matter chargeback rebate sale return pharmaceutical business carrying value intermune goodwill relate pharmaceutical division carry value product intangible asset uncertain tax position acquisition flatiron health inc key audit matter matter professional judgement significance audit consolidated financial statement current period matter address context audit consolidated financial statement form opinion thereon provide separate opinion matter roche finance report statutory auditor report roche group chargeback rebate sale return pharmaceuticals business key audit matter response group pharmaceutical business make sale audit procedure include sample customer fall certain commercial basis obtain management calculation accrue governmentmandate contract purchasing liability provision account receivable deduction reimbursement arrangement significant recalculating amount validate reasonableness medicaid b drug discount program key assumption reference internal external group provide right return customer source include term applicable contract certain product return period case government pricing information historical chargeback extend year future arrangement rebate historical sale return level current result deduction gross amount invoice arrive trend revenue create obligation group provide customer chargeback rebate consider accuracy management estimate credit sale return estimate amount deduct previous year compare historical accrue liability gross sale record accrue liability rebate provision account receivable deduction record provision sale return deduction actual settlement assess change account receivable chargeback estimate accrual rate estimate include base analysis exist contractual legislatively respond increase utilisation b drug mandate obligation historical trend group discount program compare accrual rate experience current chargeback rebate payment sale return trend management determine accrue liability deduction account receivable expect chargeback consider adequacy group revenue rebate predominantly medicaid chf recognition accounting policy include recognition million necessary december additionally measurement deduction gross sale relate provision sale return mainly relate product chargeback rebate sale return relate near loss exclusivity chf million record disclosure december focus area arrangement complex establish appropriate yearend position require significant judgement estimation management assumption require estimate provision sale return complicated give recent impending loss exclusivity group pharmaceutical product information chargeback rebate sale return pharmaceutical business refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note revenue note account receivable note current liability note provision contingent liability roche finance report roche group statutory auditor report carry value intermune goodwill relate pharmaceutical division key audit matter response january group hold goodwill chf audit procedure include assess million arise past acquisition pharmaceutical group forecast procedure integrity division principally genentech intermune discount cash flow model management small technology transaction product transaction prepare valuation challenge robustness goodwill test annually impairment addition key assumption determine recoverable assess impairment reporting date amount include identification allocation cgu include management reassessment cgus year management undertake reassessment year forecast cash flow growth rate cashgenerate unit cgus allocate discount rate base understand commercial goodwill pharmaceutical division management prospect product market require apply judgement allocate goodwill commercialise appropriate business assess future performance prospect cgu follow valuation specialist assist reassessment management record impairment evaluate assumption methodology respect intermune goodwill chf million management particular relate discount rate compare relevant assumption impairment testing use projection future cash flow industry economic forecast addition identify base recent longterm forecast approve analyse change assumption prior period management include estimate sale volume pricing assessment consistency assumption longterm forecast project year perform comparison assumption publicly available datum perform retrospective focus particular intermune goodwill light assessment accuracy management past judgement estimation require projection compare historical forecast actual result impairment record year assess group disclosures sensitivity outcome impairment assessment change key assumption reflect risk inherent valuation goodwill information carry value goodwill relate pharmaceutical division refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note goodwill roche finance report statutory auditor report roche group carry value product intangible asset key audit matter response group significant product intangible asset audit procedure include challenge december chf million acquire robustness key assumption determine business combination inlicense arrangement recoverable amount include forecast revenue useful comprise product intangible use chf million life discount rate challenge base amortise product intangible available understand commercial prospect individual use chf million amortise impairment product relevant business area market assessment carry product intangible operate valuation specialist evidence asset impair assist evaluate assumption methodologie intangible asset available use management relation discount rate test impairment annually assessment relation key input project pricing volume product project product intangible use chf million predominantly share therapeutic area vitro diagnostic market relate acquire product launch compare relevant assumption industry forecast key risk ability successfully commercialise review analyst commentary retrospective product concern large single intangible asset arise assessment accuracy previous projection acquisition intermune relate esbriet compare management assumption external datum chf million focus product intangible available example case esbriet use previous impairment record perform sensitivity analysis individual intangible low level headroom assessment asset impairment model assess level sensitivity recoverability involve forecasting discount key assumption focus work area future cash flow inherently judgemental key assess management allowance risk estimate assumption include revenue growth timing impact loss exclusivity discount rate product intangible available use audit development commercialisation compete include assess reasonableness management product driver revenue growth include persistence assumption probability obtain regulatory rate treatment rate market share approval comparison industry practice past history consideration group internal governance product intangible available use chf million approval process interview number represent inprocess research development senior research development commercial personnel asset inherent uncertainty research order understand challenge assumption development process intangible asset available use particularly risk impairment impairment assessment require management key assumption judgements clinical technical commercial viability new product accordingly focus audit work area risk include inability achieve successful trial result obtain require clinical regulatory approval highly competitive business environment therapeutic area group significant asset research development information carry value productrelate intangible asset refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note intangible asset roche finance report roche group statutory auditor report uncertain tax position key audit matter response group operate wide range different audit procedure include obtain tax jurisdiction world subject understand uncertain tax position inquiry occasional challenge local tax authority respect employee tax department management crossborder transfer pricing arrangement good affiliate review documentation relation service finance transactionrelate tax matter correspondence tax authority verify connection integration investment divestment tax exposure consider provide licensing contract area particular focus include necessary transfer pricing arrangement relate group manufacture supply chain significant item challenge management judgement eventual resolution national tax liability uncertain group tax authority double taxation conflict pende tax recognise accrual reflect management good audits estimate tax exposure assistance estimate outcome base fact know local country tax specialist significant relevant jurisdiction group open tax transfer uncertain tax position work include consideration pricing matter tax authority range thirdparty transfer pricing study use possible outcome broad december available past experience tax authority group recognise current income tax liability respective jurisdiction additionally tax chf million include accrual uncertain specialist expertise assess appropriateness tax position key assumption management conclude good estimate outcome focused area estimate amount tax receivable payable require significant level audit approach include additional audit procedure expertise judgement perform group level consider significant uncertain tax position particular transfer price apply good service intellectual property right information uncertain tax position refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note income taxis roche finance report statutory auditor report roche group acquisition flatiron health inc key audit matter response group acquire flatiron health inc flatiron health audit procedure relation acquisition flatiron april total consideration usd million health include inspection legal consideration primarily allocate intangible asset agreement support transaction examine goodwill chf million chf million information contain diligence valuation respectively report internal management presentation board director acquisition flatiron health require management apply judgement identify value intangible challenge appropriateness methodology asset allocation goodwill arise management value identify intangible asset transaction cashgenerating unit benefit compare useful economic life intangible synergy identify asset similar technology platform base understand technology platform business key assumption relate valuation area flatiron health operate addition intangible asset include revenue growth discount rate consider appropriate range alternative obsolescence competitive environment particular focused rate valuation flatiron health technology platform require additional consideration relate applied support valuation specialist obsolescence rate evaluate key estimate assumption management purchase price allocation evaluation goodwill arise transaction attribute focus appropriateness discount rate roche pharmaceutical cashgenerating unit apply key assumption revenue reflect benefit group oncology research growth competitive environment challenge development activity use flatiron health assumption base sector expertise reference realworld evidence transaction similar nature perform sensitivity analysis key assumption procedure hold inquiry management external valuer obtain understand flatiron health realworld evidence roche business expect synergy justify level goodwill recognise acquisition assess appropriateness management decision allocate goodwill roche pharmaceutical cashgenerating unit assess group disclosure relation acquisition meet requirement relevant accounting standard information acquisition flatiron health inc refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note merger acquisition roche finance report roche group statutory auditor report information annual report board director responsible information annual report information comprise information include annual report include consolidated financial statement standalone financial statement company remuneration report auditor report thereon opinion consolidated financial statement cover information annual report express form assurance conclusion thereon connection audit consolidated financial statement responsibility read information annual report consider information materially inconsistent consolidated financial statement knowledge obtain audit appears materially misstate base work perform conclude material misstatement information require report fact report regard responsibility board director consolidate financial statement board director responsible preparation consolidate financial statement true fair view accordance ifrs provision swiss law internal control board director determine necessary enable preparation consolidated financial statement free material misstatement fraud error prepare consolidated financial statement board director responsible assess group ability continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate group cease operation realistic alternative auditor responsibility audit consolidated financial statement objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law isa swiss auditing standard detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial statement audit accordance swiss law isa swiss auditing standard exercise professional judgment maintain professional scepticism audit identify assess risk material misstatement consolidated financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure conclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease continue go concern roche finance report statutory auditor report roche group evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement represent underlie transaction event manner achieve fair presentation obtain sufficient appropriate audit evidence financial information entity business activity group express opinion consolidated financial statement responsible direction supervision performance group audit remain solely responsible audit opinion communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit provide board director relevant committee statement comply relevant ethical requirement independence communicate relationship matter reasonably think bear independence applicable relate safeguard matter communicate board director relevant committee determine matter significance audit consolidated financial statement current period key audit matter describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communication report legal regulatory requirement accordance article para item co swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ag mark baillache marc ziegler license audit expert license audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve roche finance report roche group independent reasonable assurance report internal control financial reporting independent reasonable assurance report internal control financial reporting board director roche holding ltd basel engage board director carry reasonable assurance engagement design implementation operating effectiveness system internal control financial reporting roche group place december management roche holding ltd assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso responsibility board director management board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting entitys internal control financial reporting process design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs entitys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entitys asset material effect entitys financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate responsibility responsibility examine design implementation effectiveness company internal control financial reporting report thereon form independent reasonable assurance conclusion base evidence obtain conduct engagement accordance international standard assurance engagement isae assurance engagement audits review historical financial information issue international auditing assurance standard board standard require plan perform procedure obtain reasonable assurance effective internal control financial reporting maintain material respect procedure select depend judgement include assessment risk material misstatement design implementation effectiveness company internal control financial reporting examination include obtain understand internal control financial reporting testing evaluate design implementation operating effectiveness internal control base assess risk perform procedure consider necessary circumstance roche finance report independent reasonable assurance report internal control financial reporting roche group independence quality control firm apply international standard quality control accordingly maintain comprehensive system quality control include document policy procedure compliance ethical requirement professional standard applicable legal regulatory requirement comply independence ethical requirement code ethic professional accountant issue international ethic standard board accountant found fundamental principle integrity objectivity professional competence care confidentiality professional behaviour conclusion conclusion form basis subject matter outline report believe evidence obtain sufficient appropriate provide basis conclusion opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg ag mark baillache marc ziegler license audit expert license audit expert basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report roche group multiyear overview supplementary information sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group alternative performance measure financial information include financial review include certain alternative performance measure apm accounting measure define ifrs particular core result net work capital net operating asset free cash flow constant exchange rate apm instead consider alternative group consolidated financial result base ifrs apm comparable similarly title measure disclose company apm present financial review relate performance current year comparative period core result core result allow assessment group actual result define ifrs underlie performance business core result concept internal management business base ifrs result follow adjustment global restructuring plan note exclude amortisation impairment intangible asset note impairment goodwill note exclude acquisition accounting impact accounting merger acquisition transaction alliance arrangement financial review exclude discontinued operation currently exclude legal environmental case financial review exclude global issue outside healthcare sector group control exclude material treasury item major debt restructuring currently exclude pension plan settlement note exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial review roche finance report roche group multiyear overview supplementary information core result reconciliation millions chf normali global intangible alliance legal pension sation restruc amorti intangible trans environ plan global ecp tax ifrs ture sation impairment action mental settlement issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation millions chf normali global intangible alliance legal pension sation restruc amorti intangible trans environ plan global ecp tax ifrs ture sation impairment action mental settlement issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche finance report multiyear overview supplementary information roche group divisional core result reconciliation million chf global intangible alliance legal pension restruc amorti intangible trans environ plan ifrs ture sation impairment action mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation million chf global intangible alliance legal pension restruc amorti intangible trans environ plan ifrs ture sation impairment action mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary information core ep basic core net income attributable roche shareholder chf million weight average number share nonvoting equity security issue million core earning share basic chf core ep diluted core net income attributable roche shareholder chf million increase noncontrolle interest share core net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue calculate diluted earning share million core earning share diluted chf free cash flow free cash flow assess group ability generate cash require conduct maintain operation indicate group ability generate cash finance dividend payment repay debt undertake merger acquisition activity free cash flow concept internal management business operate free cash flow calculate base ifrs operating profit adjust certain cash item movement net work capital capital expenditure investment property plant equipment intangible asset operate free cash flow different cash flow operating activity define ias include capital expenditure responsibility divisional management exclude income taxis pay responsibility divisional management cash outflow define benefit plan allocate operate free cash flow base current service cost residual allocate treasury activity free cash flow calculate operate free cash flow adjust treasury activity taxis pay free cash flow different total cash flow define ia exclude dividend payment cash inflowsoutflow financing activity issuancerepayment debt purchasesale marketable security cash inflowsoutflow merger acquisition divestment roche finance report multiyear overview supplementary information roche group operate free cash flow free cash flow calculate show table additional commentary adjustment item give financial review operate free cash flow reconciliation million chf cash flow operating activity ifrs basis accordance ia add income taxis pay deduct investment property plant equipment investment intangible asset disposal property plant equipment disposal intangible asset pension postemployment benefit add total payment define benefit plan deduct allocation payment operate free cash flow operating item operate free cash flow free cash flow reconciliation million chf cash flow operating activity ifrs basis accordance ia deduct investment property plant equipment investment intangible asset disposal property plant equipment disposal intangible asset interest pay operating item treasury item free cash flow roche finance report roche group multiyear overview supplementary information supplementary information calculate divisional operate free cash flow show table divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct utilisation provision proceed disposal total operating profit cash adjustment ebitda group use earning interest tax depreciation amortisation ebitda internal management report external communication opinion group management operate free cash flow give useful consistent measurement cash earning ebitda include noncash item provision allowance trade receivables inventory certain noncash entry arise acquisition accounting pension accounting convenience reader use ebitda provide table start point use core result exclude amortisation impairment goodwill intangible asset ebitda core result million chf pharmaceutical diagnostic corporate group ebitda core operate profit depreciation impairment property plant equipment core basis ebitda margin sale roche finance report multiyear overview supplementary information roche group net operating asset net operating asset allow assessment group operate performance business independently finance tax activity net operating asset calculate property plant equipment goodwill intangible asset net work capital longterm net operating asset minus provision calculation net operating asset disclose note annual financial statement show table net operating asset reconciliation millions chf taxation pharmaceutical diagnostic corporate treasury group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset net operating asset reconciliation millions chf taxation pharmaceutical diagnostic corporate treasury group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset roche finance report roche group multiyear overview supplementary information net debt net debt monitor group overall short longterm liquidity net debt calculate sum total debt longterm shortterm marketable security cash cash equivalent net debt calculation include detail movement current year show table financial review net work capital net working capital assess group efficiency utilise asset shortterm liquidity net trade work capital calculate trade receivables inventory minus trade payable net work capital calculate net trade work capital adjust receivables payable net work capital net trade work capital calculation show table pharmaceutical division diagnostic division corporate financial review constant exchange rate certain percentage change financial review calculate constant exchange rate cer allow assessment group financial performance effect exchange rate fluctuation eliminate percentage change constant exchange rate calculate simulation reconsolidate current report period prior period number constant currency exchange rate equal average exchange rate prior year example cer change line item equivalent calculate average exchange rate year end december line item line item subsequently calculate change percent respect recalculate number foreign exchange gain loss exclude calculation cer growth rate earning share disclosure country significant devaluation local currency current year simulation use average exchange rate current year instead prior year avoid cer growth rate artificially inflate roche finance report roche security roche group roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr standard poors index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july information table restate change ratio adr effective january change ratio adr effective january change ratio adr effective february roche finance report roche group roche security number share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number share nonvoting equity security genussscheine hold total issue datum share nonvoting equity security chf earning basic earning dilute core earning basic core earning dilute equity attributable roche shareholder dividend c stock price share b open high low yearend stock price nonvoting equity security genussschein b open high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities b stock price datum reflect daily closing price c dividend propose board director stock code share nonvoting equity security american depositary receipt adr swiss exchange ro rog bloomberg ro sw rog vx rhhby reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statement note financial statement summary significant accounting policy ignificant shareholder hareholder equity fulltime equivalent employee contingent liability board executive shareholding appropriation available earning statutory auditor report general meeting roche holding ltd basel roche finance report roche holding ltd basel financial statement financial statement balance sheet millions chf december december current asset cash cash equivalent marketable security account receivable group company shortterm loan group company total current asset noncurrent asset longterm loan group company investment total noncurrent asset total asset shortterm liability account payable group company interestbeare liability group company shortterm liability total shortterm liability longterm liability provision total longterm liability total liability shareholder equity share capital nonvoting equity security genussscheine pm pm legal retain earning general legal retain earning voluntary reserve retain earning free reserve special reserve available earning balance bring forward previous year net income year total shareholder equity total shareholder equity liability pm pro memoria nonvoting equity security genussscheine nominal value roche finance report financial statement roche holding ltd basel income statement millions chf year end december income income investment dividend income financial income interest income loan group company income marketable security guarantee fee income group company income total income expense administration expense expense financial expense direct taxis total expense net income roche finance report roche holding ltd basel note financial statement note financial statement summary significant accounting policy basis preparation financial statement roche holding ltd basel company prepare accordance provision swiss law accounting financial report nd title swiss code obligation co prescribe law significant accounting principle apply describe company prepare consolidated financial statement accordance recognise accounting standard international financial reporting standard accordance co company decide forgo present additional information audit fee note cash flow statement valuation method translation foreign currency marketable security report low cost market value financial asset include investment report cost appropriate writedown equity instrument recognise cost deduct equity time purchase equity instrument sell gain loss recognise income statement asset liability denominate foreign currency translate swiss franc yearend rate exchange investment translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer investment direct indirect investment company list note roche group annual financial statement list exclude chugais subsidiary material company notably company inactive dormant liquidation ownership interest equal voting right taxis direct taxis include corporate income capital taxis shareholder equity share capital previous year share capital amount chf million share capital consist bearer share nominal value chf include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate roche finance report note financial statement roche holding ltd basel equity instrument december company hold roche share nonvoting equity security company purchase sell roche share nonvoting equity security company subsidiary meet definition requirement article b co hold equity instrument roche group annual financial statement entity mainly foundation include consolidation qualify subsidiary article b co movement recognise amount million chf legal voluntary reserve retain earning retain free special available equity total share capital earning reserve reserve earning instrument equity january net income dividend transaction equity instrument december net income dividend transaction equity instrument december net income dividend transaction equity instrument december contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december chf billion chf billion describe note roche group annual financial statement significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company roche finance report roche holding ltd basel note financial statement control shareholder december base information supply group shareholder group pool voting right own share represent issue share group consist ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri dr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool december base information supply group share share own novartis hold ag basel participation fulltime equivalent employee annual average number fulltime equivalent employee exceed people board executive shareholding board director director mr andr hoffmann dr andreas oeri certain member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table shareholding member board director nonvoting equity security share genussscheine ch franz hoffmann j bell j brown p bulcke hauser rp lifton e oeri b poussot schwan b c suessmuth dyckerhoff c c pr voser total include share hold shareholder group pool voting right b member corporate executive committee dr schwans shareholdings disclose table c jointly hold close relative close relative hauser hold nonvoting equity security genussscheine e rp lifton hold roche american depositary receipt adr adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july roche finance report note financial statement roche holding ltd basel corporate executive committee end year member corporate executive committee person closely associate hold share nonvoting equity security show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan r diggelmann na na heuer na na c hippe ga keller b oday wilbur total equity compensation award ssar rsus roche performance share plan b close relative dr keller hold roche share roche share c heuer hold restrict stock unit rsus whereof issue rsus term vest condition award disclose note roche group annual financial statement close relative heuer hold roche nonvoting equity security december members corporate executive committee hold stocksettle stock appreciation right ssar show table term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page ssar award hold december year issue total schwan heuer hippe ga keller oday wilbur total cec strike price chf expiry date mar mar mar mar mar mar mar close relative heuer hold ssar issue strike price chf expiry date march grant value ssar chf restrict stock unit rsus remuneration component corporate executive committee replace award correspond performance share plan psp award rsu awards vest recipient year non vote equity security remain block year december member corporate executive committee hold rsus michael heuer disclose roche finance report roche holding ltd basel note financial statement december members corporate executive committee show table hold psp award psp performance cycle term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page award result zero nonvoting equity security share value adjustment depend achievement performance target discretion board director vest nonvoting equity security share remain block year end cycle performance target achieve accordingly participant receive originally target share total target number award outstanding performance cycle december show table roche performance share plan psp award hold december psp psp schwan heuer hippe ga keller oday b wilbur total cec allocation date feb feb heuer participate psp programme b potential award reduce resignation information relate number value right option award grant employee roche group member board director corporate executive committee company disclose note note roche group annual financial statement roche finance report appropriation available earning roche holding ltd basel appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year total appropriation available earning carry forward account roche finance report roche holding ltd basel statutory auditor report statutory auditor report general meeting roche holding ltd basel report audit financial statement opinion audit financial statement roche holding ltd comprise balance sheet december income statement year end note financial statement include summary significant accounting policy opinion financial statement page year end december comply swiss law company article incorporation basis opinion conduct audit accordance swiss law swiss auditing standard responsibility provision standard describe auditor responsibility audit financial statement section report independent entity accordance provision swiss law requirement swiss audit profession fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion report key audit matter base circular federal audit oversight authority key audit matter matter professional judgement significance audit financial statement current period determine key audit matter communicate report responsibility board director financial statement board director responsible preparation financial statement accordance provision swiss law company article incorporation internal control board director determine necessary enable preparation financial statement free material misstatement fraud error prepare financial statement board director responsible assess entitys ability continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate entity cease operation realistic alternative auditor responsibility audit financial statement objective obtain reasonable assurance financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law swiss auditing standard detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis financial statement roche finance report statutory auditor report roche holding ltd basel audit accordance swiss law swiss auditing standard exercise professional judgement maintain professional scepticism audit identify assess risk material misstatement financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance purpose express opinion effectiveness internal control evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure c onclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt entitys ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause entity cease continue go concern communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit provide board director relevant committee statement comply relevant ethical requirement independence communicate relationship matter reasonably think bear independence applicable relate safeguard matter communicate board director relevant committee determine matter significance audit financial statement current period key audit matter describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communication report legal regulatory requirement accordance article para item co swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ag mark baillache marc ziegler license audit expert license audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve roche finance report publish cautionary statement forwardlooke statement f hoffmannla roche ltd annual report contain certain forwardlooking statement group communication forwardlooke statement identify word basel switzerland believe expect anticipate project intend tel seek estimate future similar expression wwwrochecom discussion thing strategy goal plan intention factor cause actual result differ orderdownload publication materially future reflect forwardlooke internet rochecompublication statement contain annual report email baselwarehouseservicesrochecom pricing product initiative competitor legislative fax regulatory development economic condition delay inability obtain regulatory approval bring product medium relation market fluctuation currency exchange rate general tel financial market condition uncertaintie discovery email mediarelationsrochecom development marketing new product new use exist product include limitation negative result clinical investor relation trial research project unexpected effect pipeline tel market product increase government pricing pressure email investorrelationsrochecom interruption production loss inability obtain adequate protection intellectual property right litigation corporate sustainability committee loss key executive employee adverse tel publicity news coverage email corporatesustainabilityrochecom statement earning share growth profit annual general meeting forecast interpret mean roche march earning earning share subsequent period necessarily match exceed historical publish earning earning share roche trademark legally protect link thirdparty page provide convenience express opinion content thirdparty page expressly disclaim liability thirdparty information use roche finance report publish german english case doubt difference interpretation english version shall prevail german text reporting consist actual annual report finance report contain annual financial statement consolidated financial statement regard content management report article incorporation consist aforementioned report exception remuneration report print nonchlorine bleach fsccertifie paperf hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom e roche finance report f hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom finance report e roche finance report journey finance report recovery woman show cover roche finance report year appear cover report year midst receive treatment breast cancer photographed come powerfully cover year later enjoy life p e n n n v n p r n e r cancer modern care help advanced analytic enable roche expand colla b effective treatment create wealth new data insight oration combine available previously innovative opportunity strength unique tool therapy allow woman entire product lifecycle rd partner elevate personalise cover picture carry value chain ultimately improve healthcare new level life cover outcome patient patient